mirror of
https://github.com/msberends/AMR.git
synced 2026-11-16 04:20:53 +01:00
7665 lines
2.0 MiB
Plaintext
7665 lines
2.0 MiB
Plaintext
"","guideline","type","host","method","site","mo","rank_index","ab","ref_tbl","disk_dose","breakpoint_S","breakpoint_R","uti","is_SDD","note"
|
|
"1","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"2","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"3","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"6","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"8","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"9","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"10","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"11","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"12","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"13","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"14","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"15","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"16","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"17","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"18","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"19","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"20","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"21","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"22","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"23","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"24","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"25","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"26","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,4,FALSE,FALSE,NA
|
|
"27","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"28","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"29","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"30","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"31","EUCAST 2026","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"32","EUCAST 2026","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"33","EUCAST 2026","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA
|
|
"34","EUCAST 2026","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"35","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"36","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"37","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"38","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"39","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"40","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"41","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"42","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"43","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"44","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"45","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"46","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"47","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA
|
|
"48","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"49","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"50","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"51","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"52","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA
|
|
"53","EUCAST 2026","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"54","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA
|
|
"55","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"56","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"57","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"58","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"59","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"60","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"61","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"62","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"63","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA
|
|
"64","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"65","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"66","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"67","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"68","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA
|
|
"69","EUCAST 2026","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"70","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA
|
|
"71","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"72","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"73","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"74","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"75","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"76","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"77","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"78","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"79","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"80","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"81","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"82","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"83","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"84","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"85","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"86","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"87","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"88","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"89","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"90","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"91","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"92","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"93","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"94","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"95","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"96","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"97","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"98","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"99","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"100","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"101","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"102","EUCAST 2026","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"103","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"104","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"105","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"106","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"107","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.25,FALSE,FALSE,NA
|
|
"108","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"109","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"110","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"111","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"112","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"113","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,NA
|
|
"114","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"115","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,18,FALSE,FALSE,NA
|
|
"116","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"117","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"118","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"119","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,NA
|
|
"120","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"121","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"122","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"123","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",14,14,FALSE,FALSE,NA
|
|
"124","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"125","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"126","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"127","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"128","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"129","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"130","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"131","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"132","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"133","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"134","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"135","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",25,25,FALSE,FALSE,NA
|
|
"136","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"137","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
|
|
"138","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
|
|
"139","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,27,FALSE,FALSE,NA
|
|
"140","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"141","EUCAST 2026","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"142","EUCAST 2026","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"143","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"144","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"145","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"146","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,28,FALSE,FALSE,NA
|
|
"147","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"148","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
|
|
"149","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"150","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"151","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"152","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"153","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"154","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",42,42,FALSE,FALSE,NA
|
|
"155","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"156","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"157","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"158","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"159","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"160","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"161","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"162","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"163","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"164","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"165","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"166","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"167","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"168","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"169","EUCAST 2026","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
|
|
"170","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"171","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"172","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"173","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"174","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"175","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"176","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"177","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"178","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"179","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"180","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"181","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"182","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"183","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"184","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"185","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"186","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"187","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"188","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"189","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"190","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"191","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"192","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"193","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA
|
|
"194","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"195","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"196","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"197","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"198","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"199","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"200","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"201","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"202","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"203","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"204","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"205","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"206","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"207","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"208","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"209","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"210","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"211","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"212","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"213","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"214","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"215","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA
|
|
"216","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"217","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"218","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"219","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"220","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"221","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"222","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"223","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"224","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"225","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"226","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"227","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"228","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"229","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"230","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"231","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"232","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"233","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"234","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"235","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA
|
|
"236","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"237","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"238","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"239","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"240","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"241","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"242","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"243","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"244","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"245","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"246","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"247","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"248","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"249","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"250","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"251","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"252","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"253","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"254","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"255","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,NA
|
|
"256","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"257","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"258","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"259","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"260","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"261","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",NA,33,FALSE,FALSE,NA
|
|
"262","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
|
|
"263","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"264","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"265","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"266","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"267","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"268","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"269","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"270","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",33,33,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"271","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"272","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"273","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"274","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CTX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"275","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"276","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"277","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"278","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"279","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"280","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"281","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"282","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"283","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"284","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"285","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"286","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"287","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"288","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"289","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,NA
|
|
"290","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"291","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"292","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"293","EUCAST 2026","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"294","EUCAST 2026","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"295","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"296","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"297","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,NA
|
|
"298","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"299","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"300","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"301","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"302","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"303","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"304","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",28,28,FALSE,FALSE,NA
|
|
"305","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"306","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,NA
|
|
"307","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"308","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"309","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"310","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"311","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"312","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"313","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"314","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"315","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"316","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"317","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"318","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"319","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"320","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"321","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"322","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"323","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"324","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"325","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"326","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"327","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"328","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"329","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"330","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"331","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"332","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"333","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"334","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"335","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"336","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"337","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"338","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"339","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"340","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"341","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"342","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"343","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"344","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"345","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"346","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"347","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"348","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"349","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"350","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"351","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"352","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",24,24,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"353","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"354","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"355","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"356","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"357","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"358","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"359","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"360","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"361","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"362","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"363","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"364","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"365","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"366","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"367","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"368","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",14,14,FALSE,FALSE,NA
|
|
"369","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"370","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"371","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"372","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",12,12,FALSE,FALSE,NA
|
|
"373","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"374","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"375","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"376","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"377","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"378","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"379","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"380","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"381","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",22,22,FALSE,FALSE,NA
|
|
"382","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"383","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",13,13,FALSE,FALSE,NA
|
|
"384","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"385","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"386","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"387","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",10,10,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
|
|
"388","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"389","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility can be inferred from ampicillin."
|
|
"390","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,"[1] Susceptibility can be inferred from ampicillin."
|
|
"391","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"392","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,NA
|
|
"393","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"394","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"395","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"396","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"397","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"398","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,NA
|
|
"399","EUCAST 2026","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
|
|
"400","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"401","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"402","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"403","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"404","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,NA
|
|
"405","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"406","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",22,22,FALSE,FALSE,NA
|
|
"407","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"408","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"409","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"410","EUCAST 2026","human","human","MIC","other indications","B_ENTRC_FCLS",2,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"411","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"GEP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA
|
|
"412","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"413","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"414","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"415","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA
|
|
"416","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"417","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"418","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",50,18,FALSE,FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
|
|
"419","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
|
|
"420","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"421","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"422","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"423","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"424","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"425","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA
|
|
"426","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"427","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"428","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"429","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"430","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"431","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"432","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"433","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"434","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"435","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"GEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA
|
|
"436","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"437","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"438","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"439","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA
|
|
"440","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"441","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA
|
|
"442","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"443","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"444","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"445","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"446","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"447","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA
|
|
"448","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"449","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.."
|
|
"450","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"451","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"452","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"453","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"454","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"455","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"456","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"457","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"458","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"459","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"460","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"461","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"462","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"463","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"464","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"465","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"466","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"467","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"468","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"469","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"470","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"471","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"472","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"473","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"474","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"475","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"476","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"477","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"478","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"479","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"480","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"481","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"482","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"483","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"484","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"485","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"486","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"487","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"488","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"489","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"490","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"491","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"492","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"493","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"494","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"495","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"496","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"497","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"498","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"499","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"500","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"501","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"502","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"503","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"504","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"505","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"506","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"507","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"508","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"509","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"510","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"511","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"512","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"513","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"514","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"515","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"516","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"517","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"518","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"519","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"520","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"521","EUCAST 2026","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"522","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"523","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"524","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"525","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"526","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"527","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"528","EUCAST 2026","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"529","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"530","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"531","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",32,32,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"532","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"533","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"534","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"535","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"536","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"537","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"538","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"539","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"540","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"541","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"542","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"543","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"544","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"545","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"546","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"547","EUCAST 2026","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications."
|
|
"548","EUCAST 2026","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"549","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"550","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"551","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"552","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"553","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"554","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"555","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"556","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"557","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"558","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"559","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"560","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"561","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"562","EUCAST 2026","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"563","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"564","EUCAST 2026","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"565","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"566","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"567","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"568","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"569","EUCAST 2026","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"570","EUCAST 2026","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"571","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"572","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"573","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"574","EUCAST 2026","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"575","EUCAST 2026","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"576","EUCAST 2026","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"577","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"578","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"579","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"580","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"581","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"582","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"583","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"584","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"585","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"AMC","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",22,22,FALSE,FALSE,NA
|
|
"586","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"587","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"588","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"589","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"590","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"591","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"592","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"593","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"594","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"595","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"596","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"597","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"598","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
|
|
"599","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"600","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"601","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"602","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"603","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"604","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"605","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,NA
|
|
"606","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"607","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"608","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"609","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"610","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"611","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"612","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"613","EUCAST 2026","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"614","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"615","EUCAST 2026","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"616","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA
|
|
"617","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"618","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"619","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"620","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"621","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"622","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"623","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"624","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA
|
|
"625","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"626","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"627","EUCAST 2026","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"628","EUCAST 2026","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"629","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"630","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"631","EUCAST 2026","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","1 unit",13,13,FALSE,FALSE,NA
|
|
"632","EUCAST 2026","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"633","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"634","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"635","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"636","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"637","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"638","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"639","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"640","EUCAST 2026","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"641","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"642","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"643","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"644","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"645","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"646","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"647","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"648","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"649","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"650","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"651","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"652","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,8,FALSE,FALSE,NA
|
|
"653","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"654","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"655","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"656","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"657","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"658","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"659","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"660","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"661","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"662","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"663","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"664","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"665","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"666","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"667","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"668","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"669","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"670","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"671","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"672","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"673","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"674","EUCAST 2026","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"675","EUCAST 2026","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"676","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"677","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"678","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"679","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"680","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"681","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"682","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"683","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"684","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"685","EUCAST 2026","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] For bedaquiline, breakpoints were determined using the EUCAST reference method."
|
|
"686","EUCAST 2026","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination.
|
|
3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods."
|
|
"687","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"688","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"689","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"690","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"691","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"692","EUCAST 2026","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"693","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,FALSE,FALSE,NA
|
|
"694","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"695","EUCAST 2026","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,1,FALSE,FALSE,NA
|
|
"696","EUCAST 2026","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,1,FALSE,FALSE,NA
|
|
"697","EUCAST 2026","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"698","EUCAST 2026","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"699","EUCAST 2026","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"700","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"701","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
|
|
"702","EUCAST 2026","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"703","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"704","EUCAST 2026","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"705","EUCAST 2026","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"706","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"707","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"708","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"709","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"710","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",15,15,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"711","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"712","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"713","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"714","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",37,37,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"715","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"716","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"717","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"718","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"719","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"720","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",18,18,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"721","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"722","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"723","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"724","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"725","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"726","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",22,22,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"727","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.."
|
|
"728","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"729","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"730","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"731","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"732","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"733","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"734","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"735","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"736","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"737","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"738","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"739","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"740","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"741","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"742","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"743","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"744","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"745","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"746","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"747","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,NA
|
|
"748","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"749","EUCAST 2026","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"750","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"751","EUCAST 2026","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"752","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA
|
|
"753","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"754","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"755","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"756","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"757","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"758","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"759","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"760","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"761","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"762","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
|
|
"763","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"764","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"765","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",40,40,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"766","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"767","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"768","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"769","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"770","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"771","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"772","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"773","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"774","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"775","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,NA
|
|
"776","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"777","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"778","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"779","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"780","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"781","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"782","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"783","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"784","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"785","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"786","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"787","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"788","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"789","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"790","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
|
"791","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"792","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"793","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"794","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"795","EUCAST 2026","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"796","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"797","EUCAST 2026","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"798","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA
|
|
"799","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"800","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"801","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"802","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"803","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"804","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"805","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"806","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"807","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"808","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"809","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"810","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"811","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"812","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,18,FALSE,FALSE,NA
|
|
"813","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"814","EUCAST 2026","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"815","EUCAST 2026","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA
|
|
"816","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"817","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"818","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"819","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"820","EUCAST 2026","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"821","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"822","EUCAST 2026","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"823","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"824","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"825","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"826","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"827","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"828","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"829","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"830","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"831","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",23,23,FALSE,FALSE,"[4] See table of dosages for dosing for different indications."
|
|
"832","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications."
|
|
"833","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"834","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"835","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"836","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"837","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"838","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"839","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"840","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"841","EUCAST 2026","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,14,FALSE,FALSE,NA
|
|
"842","EUCAST 2026","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"843","EUCAST 2026","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA
|
|
"844","EUCAST 2026","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"845","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",14,14,FALSE,FALSE,NA
|
|
"846","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"847","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"848","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"849","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"850","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"851","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"852","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"853","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"854","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"855","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"856","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"857","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"858","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"859","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"860","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"861","EUCAST 2026","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"862","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","1 unit",17,17,FALSE,FALSE,NA
|
|
"863","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"864","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"865","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"866","EUCAST 2026","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"867","EUCAST 2026","human","human","DISK",NA,"B_SERRT",3,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,15,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"868","EUCAST 2026","human","human","MIC",NA,"B_SERRT",3,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"869","EUCAST 2026","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"870","EUCAST 2026","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"871","EUCAST 2026","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"872","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"873","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"874","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"875","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"876","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"877","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"878","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"879","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"880","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"881","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"882","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"883","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"884","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"885","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"886","EUCAST 2026","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"887","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,NA
|
|
"888","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"889","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"890","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",24,24,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"891","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"892","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"893","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"894","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"895","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"896","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,TRUE,FALSE,NA
|
|
"897","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA
|
|
"898","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"899","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"900","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"901","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"902","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"903","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"904","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"905","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA
|
|
"906","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"907","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"908","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"909","EUCAST 2026","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"910","EUCAST 2026","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"911","EUCAST 2026","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"912","EUCAST 2026","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"913","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"914","EUCAST 2026","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"915","EUCAST 2026","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"916","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"917","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"918","EUCAST 2026","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"919","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"920","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"921","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"922","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"923","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"924","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"925","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"926","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"927","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"928","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"929","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"930","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"931","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"932","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used."
|
|
"933","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used."
|
|
"934","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"935","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"936","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"937","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"938","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"939","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"940","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"941","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"942","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"943","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"944","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"945","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"946","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"947","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"948","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"949","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"950","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"951","EUCAST 2026","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"952","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"953","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"954","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"955","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"956","EUCAST 2026","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"957","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"958","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"959","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"960","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"961","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"962","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"963","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"964","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"965","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"966","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"967","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"968","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"969","EUCAST 2026","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"970","EUCAST 2026","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"971","EUCAST 2026","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"972","EUCAST 2026","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 unit",26,26,FALSE,FALSE,NA
|
|
"973","EUCAST 2026","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"974","EUCAST 2026","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"975","EUCAST 2026","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"976","EUCAST 2026","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
|
"977","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"GEP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,TRUE,FALSE,NA
|
|
"978","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"979","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA
|
|
"980","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"981","EUCAST 2026","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"982","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"983","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"984","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"985","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"986","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"987","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"988","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"989","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"990","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"991","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"992","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"993","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,32,32,FALSE,FALSE,NA
|
|
"994","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"995","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"996","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"997","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"998","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"999","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1000","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1001","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1002","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1003","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1004","EUCAST 2026","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1005","EUCAST 2026","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"1006","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1007","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1008","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1 unit",23,23,FALSE,FALSE,NA
|
|
"1009","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1010","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"1011","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1012","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1013","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"1014","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1015","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1016","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1017","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1018","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1019","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1020","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1021","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1022","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1023","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1024","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1025","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1026","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1027","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1028","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1029","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"1030","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1031","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"1032","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA
|
|
"1033","EUCAST 2026","human","human","DISK",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1 unit",18,18,FALSE,FALSE,NA
|
|
"1034","EUCAST 2026","human","human","MIC",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1035","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"1036","EUCAST 2026","human","human","DISK","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",22,19,FALSE,FALSE,NA
|
|
"1037","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1038","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1039","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1040","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1041","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1042","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1043","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"1044","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1045","EUCAST 2026","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"1046","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"1047","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1048","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"1049","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"1050","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1051","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1052","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1053","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"1054","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1055","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"1056","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1057","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1058","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1059","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1060","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1061","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1062","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1063","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1064","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"1065","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1066","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"1067","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1068","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"1069","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1070","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1071","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"1072","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1073","EUCAST 2026","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1074","EUCAST 2026","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1075","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1076","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1077","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1078","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1079","EUCAST 2026","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1080","EUCAST 2026","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"1081","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1082","EUCAST 2026","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"1083","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,1,FALSE,FALSE,NA
|
|
"1084","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1085","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"1086","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1087","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1088","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1089","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1090","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1091","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1092","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1093","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1094","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1095","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1096","EUCAST 2026","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"1097","EUCAST 2026","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,NA
|
|
"1098","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"1099","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1100","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"1101","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1102","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"1103","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"1104","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"1105","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1106","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"1107","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1108","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"1109","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1110","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1111","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"1112","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1113","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1114","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"1115","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1116","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"1117","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1118","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1119","EUCAST 2026","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1120","EUCAST 2026","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,12,FALSE,FALSE,NA
|
|
"1121","EUCAST 2026","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA
|
|
"1122","EUCAST 2026","human","human","DISK","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",12,12,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1123","EUCAST 2026","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1124","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,1,FALSE,FALSE,NA
|
|
"1125","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1126","EUCAST 2026","human","human","MIC","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1127","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1128","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1129","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1130","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1131","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"1132","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1133","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"1134","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1135","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"1136","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1137","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"1138","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1139","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1140","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"1141","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"1142","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1143","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"1144","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1145","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"1146","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1147","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1148","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
|
|
"1149","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"1150","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1151","EUCAST 2026","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"1152","EUCAST 2026","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"1153","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1154","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1155","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1156","EUCAST 2026","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1157","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1158","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1159","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1160","EUCAST 2026","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1161","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1162","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"1163","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1164","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"1165","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1166","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1167","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1168","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1169","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1170","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1171","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1172","EUCAST 2026","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1173","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"1174","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"1175","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/20 mcg",25,25,FALSE,FALSE,NA
|
|
"1176","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"1177","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"1178","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1179","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"1180","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"1181","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"1182","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,TRUE,FALSE,NA
|
|
"1183","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"1184","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA
|
|
"1185","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"1186","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA
|
|
"1187","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"1188","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"1189","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test."
|
|
"1190","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1191","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"1192","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1193","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"1194","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,TRUE,FALSE,NA
|
|
"1195","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"1196","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1197","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"1198","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,NA
|
|
"1199","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"1200","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1201","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"1202","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1203","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"1204","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"1205","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"1206","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1207","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"1208","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"1209","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",22,22,FALSE,FALSE,"[7] See table of dosages for dosing for different indications."
|
|
"1210","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications."
|
|
"1211","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"1212","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA
|
|
"1213","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"1214","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1215","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"1216","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1217","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"1218","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA
|
|
"1219","EUCAST 2026","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"1220","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/20 mcg",22,22,FALSE,FALSE,NA
|
|
"1221","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L."
|
|
"1222","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1223","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1224","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1225","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1226","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1227","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1228","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"1229","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"1230","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"1231","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,4,FALSE,FALSE,NA
|
|
"1232","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"1233","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA
|
|
"1234","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"1235","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1236","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1237","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"1238","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"1239","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA
|
|
"1240","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1241","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",20,20,FALSE,FALSE,NA
|
|
"1242","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"1243","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"1244","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"1245","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"1246","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"1247","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,TRUE,FALSE,NA
|
|
"1248","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"1249","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"1250","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"1251","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1252","EUCAST 2026","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
|
|
"1253","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"1254","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"1255","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA
|
|
"1256","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1257","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1258","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1259","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1260","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1261","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1262","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"1263","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1264","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1265","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"1266","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"1267","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1268","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1269","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA
|
|
"1270","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"1271","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1272","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_FLAVS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1273","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_FLAVS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM."
|
|
"1274","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"AMB","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1275","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1276","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM."
|
|
"1277","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"POS","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1278","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"VOR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM."
|
|
"1279","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1280","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM."
|
|
"1281","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"VOR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM."
|
|
"1282","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NIGR",2,"AMB","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1283","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1284","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM."
|
|
"1285","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"POS","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1286","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1287","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"1288","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA
|
|
"1289","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1290","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1291","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1292","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.008,0.008,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1293","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
|
|
"1294","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1295","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1296","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA
|
|
"1297","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1298","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1299","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1300","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1301","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
|
|
"1302","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1303","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1304","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA
|
|
"1305","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1306","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,NA
|
|
"1307","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1308","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1309","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"1310","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1311","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1312","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA
|
|
"1313","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1314","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1315","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1316","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1317","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
|
|
"1318","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.001,2,FALSE,FALSE,"[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains."
|
|
"1319","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1320","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1321","EUCAST 2026","human","human","MIC",NA,"F_CRYPT_NFRM",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1322","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1323","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1324","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.001,16,FALSE,FALSE,"[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains."
|
|
"1325","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1326","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1327","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA
|
|
"1328","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1329","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
|
|
"1330","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"1331","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"1332","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1333","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1334","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"1335","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1336","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1337","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"1338","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1339","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"1340","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"1341","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"1342","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1343","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1344","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"1345","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1346","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"1347","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"1348","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1349","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1350","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1351","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1352","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1353","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1354","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"1355","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,NA
|
|
"1356","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"1357","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"1358","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1359","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1360","EUCAST 2025","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"1361","EUCAST 2025","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"1362","EUCAST 2025","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA
|
|
"1363","EUCAST 2025","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1364","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1365","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1366","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1367","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1368","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1369","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"1370","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1371","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1372","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1373","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"1374","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1375","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"1376","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,NA
|
|
"1377","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"1378","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"1379","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1380","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"1381","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA
|
|
"1382","EUCAST 2025","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"1383","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"1384","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1385","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"1386","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1387","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"1388","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1389","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"1390","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1391","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"1392","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,NA
|
|
"1393","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"1394","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"1395","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1396","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"1397","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA
|
|
"1398","EUCAST 2025","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"1399","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"1400","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1401","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"1402","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1403","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"1404","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1405","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"1406","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"1407","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"1408","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"1409","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"1410","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"1411","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"1412","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"1413","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"1414","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"1415","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1416","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1417","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1418","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1419","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"1420","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1421","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"1422","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1423","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"1424","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1425","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"1426","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1427","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1428","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1429","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"1430","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1431","EUCAST 2025","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"1432","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"1433","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1434","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"1435","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"1436","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.25,FALSE,FALSE,NA
|
|
"1437","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"1438","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1439","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"1440","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"1441","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1442","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,NA
|
|
"1443","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1444","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,18,FALSE,FALSE,NA
|
|
"1445","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1446","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1447","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1448","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,NA
|
|
"1449","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1450","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1451","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1452","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",14,14,FALSE,FALSE,NA
|
|
"1453","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1454","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"1455","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1456","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1457","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1458","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"1459","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1460","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"1461","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1462","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"1463","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1464","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",25,25,FALSE,FALSE,NA
|
|
"1465","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"1466","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",24,24,FALSE,FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
|
|
"1467","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
|
|
"1468","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,27,FALSE,FALSE,NA
|
|
"1469","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1470","EUCAST 2025","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1471","EUCAST 2025","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1472","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"1473","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1474","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1475","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,28,FALSE,FALSE,NA
|
|
"1476","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1477","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
|
|
"1478","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1479","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1480","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1481","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1482","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1483","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",42,42,FALSE,FALSE,NA
|
|
"1484","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1485","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"1486","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1487","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"1488","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1489","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"1490","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1491","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"1492","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"1493","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1494","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"1495","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1496","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1497","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1498","EUCAST 2025","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
|
|
"1499","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"1500","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1501","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"1502","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"1503","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"1504","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"1505","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"1506","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1507","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"1508","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"1509","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"1510","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"1511","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"1512","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"1513","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"1514","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"1515","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1516","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"1517","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"1518","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"1519","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1520","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"1521","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1522","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"1523","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1524","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"1525","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1526","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"1527","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1528","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"1529","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1530","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"1531","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"1532","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1533","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"1534","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"1535","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"1536","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"1537","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"1538","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"1539","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1540","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"1541","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1542","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"1543","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"1544","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"1545","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1546","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"1547","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1548","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1549","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1550","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"1551","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1552","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"1553","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"1554","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1555","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"1556","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"1557","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"1558","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"1559","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1560","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"1561","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1562","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"1563","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"1564","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"1565","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1566","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"1567","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1568","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1569","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1570","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"1571","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1572","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1573","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1574","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1575","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1576","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"1577","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1578","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"1579","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1580","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"1581","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1582","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1583","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1584","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1585","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",34,34,FALSE,FALSE,NA
|
|
"1586","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1587","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1588","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1589","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1590","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1591","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1592","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1593","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"1594","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1595","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1596","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"1597","EUCAST 2025","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"1598","EUCAST 2025","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1599","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1600","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1601","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1602","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1603","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1604","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"1605","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1606","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1607","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1608","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1609","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1610","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1611","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1612","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,NA
|
|
"1613","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1614","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1615","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1616","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1617","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"1618","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1619","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1620","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"1621","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1622","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1623","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"1624","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",10,10,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
|
|
"1625","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1626","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility can be inferred from ampicillin."
|
|
"1627","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,"[1] Susceptibility can be inferred from ampicillin."
|
|
"1628","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1629","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA
|
|
"1630","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"1631","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1632","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"1633","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1634","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1635","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA
|
|
"1636","EUCAST 2025","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
|
|
"1637","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"1638","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1639","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1640","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1641","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,FALSE,FALSE,NA
|
|
"1642","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1643","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",22,22,FALSE,FALSE,NA
|
|
"1644","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1645","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"1646","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1647","EUCAST 2025","human","human","MIC","other indications","B_ENTRC_FCLS",2,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1648","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"1649","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"1650","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"1651","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA
|
|
"1652","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"1653","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1654","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",50,18,FALSE,FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
|
|
"1655","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
|
|
"1656","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"1657","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1658","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"1659","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"1660","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1661","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA
|
|
"1662","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"1663","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"1664","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1665","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"1666","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1667","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"1668","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"1669","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"1670","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"1671","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1672","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"1673","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"1674","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA
|
|
"1675","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"1676","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA
|
|
"1677","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1678","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1679","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"1680","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1681","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1682","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1683","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1684","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1685","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1686","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"1687","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1688","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1689","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1690","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1691","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1692","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1693","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1694","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"1695","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1696","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1697","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1698","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1699","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"1700","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1701","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1702","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1703","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1704","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1705","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"1706","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1707","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1708","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1709","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1710","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1711","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1712","EUCAST 2025","human","human","DISK","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"1713","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"1714","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"1715","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"1716","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1717","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1718","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"1719","EUCAST 2025","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"1720","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"1721","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1722","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",32,32,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1723","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1724","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1725","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1726","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1727","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1728","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1729","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1730","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1731","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1732","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1733","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1734","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1735","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1736","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"1737","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"1738","EUCAST 2025","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications."
|
|
"1739","EUCAST 2025","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"1740","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1741","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1742","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1743","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1744","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1745","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1746","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1747","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1748","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1749","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1750","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1751","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1752","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1753","EUCAST 2025","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1754","EUCAST 2025","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1755","EUCAST 2025","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1756","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1757","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1758","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1759","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1760","EUCAST 2025","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1761","EUCAST 2025","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"1762","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1763","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1764","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1765","EUCAST 2025","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1766","EUCAST 2025","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"1767","EUCAST 2025","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1768","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"1769","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1770","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1771","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1772","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1773","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"1774","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"1775","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1776","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"AMC","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",22,22,FALSE,FALSE,NA
|
|
"1777","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"1778","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"1779","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"1780","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"1781","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1782","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"1783","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"1784","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1785","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"1786","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1787","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"1788","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1789","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
|
|
"1790","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"1791","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1792","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"1793","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1794","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"1795","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1796","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"1797","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1798","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"1799","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1800","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1801","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1802","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"1803","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1804","EUCAST 2025","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"1805","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"1806","EUCAST 2025","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1807","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA
|
|
"1808","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"1809","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"1810","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1811","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"1812","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1813","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1814","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"1815","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1816","EUCAST 2025","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"1817","EUCAST 2025","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1818","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"1819","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1820","EUCAST 2025","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"1821","EUCAST 2025","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1822","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1823","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1824","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"1825","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1826","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1827","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"1828","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1829","EUCAST 2025","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"1830","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1831","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1832","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1833","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1834","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1835","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"1836","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"1837","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"1838","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"1839","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"1840","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"1841","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,8,FALSE,FALSE,NA
|
|
"1842","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"1843","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1844","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1845","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1846","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1847","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1848","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1849","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1850","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"1851","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1852","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1853","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1854","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1855","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1856","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1857","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1858","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1859","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1860","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1861","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1862","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1863","EUCAST 2025","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1864","EUCAST 2025","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"1865","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"1866","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1867","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1868","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1869","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"1870","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1871","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1872","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1873","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"1874","EUCAST 2025","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
|
|
"1875","EUCAST 2025","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
|
|
"1876","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1877","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"1878","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1879","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"1880","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"1881","EUCAST 2025","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"1882","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,FALSE,FALSE,NA
|
|
"1883","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1884","EUCAST 2025","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"1885","EUCAST 2025","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"1886","EUCAST 2025","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"1887","EUCAST 2025","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"1888","EUCAST 2025","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1889","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"1890","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
|
|
"1891","EUCAST 2025","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"1892","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1893","EUCAST 2025","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1894","EUCAST 2025","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"1895","EUCAST 2025","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"1896","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"1897","EUCAST 2025","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1898","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA
|
|
"1899","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1900","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"1901","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"1902","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1903","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1904","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1905","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1906","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1907","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"1908","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"1909","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1910","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1911","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1912","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1913","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1914","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1915","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"1916","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1917","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1918","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1919","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1920","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"1921","EUCAST 2025","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1922","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"1923","EUCAST 2025","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1924","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA
|
|
"1925","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"1926","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1927","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"1928","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1929","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"1930","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"1931","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"1932","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"1933","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"1934","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"1935","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"1936","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"1937","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"1938","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,18,FALSE,FALSE,NA
|
|
"1939","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"1940","EUCAST 2025","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"1941","EUCAST 2025","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA
|
|
"1942","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"1943","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"1944","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"1945","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1946","EUCAST 2025","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1947","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"1948","EUCAST 2025","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1949","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1950","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"1951","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"1952","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"1953","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1954","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"1955","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"1956","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"1957","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",23,23,FALSE,FALSE,"[4] See table of dosages for dosing for different indications."
|
|
"1958","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications."
|
|
"1959","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"1960","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"1961","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"1962","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"1963","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"1964","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"1965","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"1966","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1967","EUCAST 2025","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,14,FALSE,FALSE,NA
|
|
"1968","EUCAST 2025","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"1969","EUCAST 2025","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA
|
|
"1970","EUCAST 2025","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1971","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",14,14,FALSE,FALSE,NA
|
|
"1972","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"1973","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1974","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"1975","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"1976","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"1977","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"1978","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1979","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1980","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"1981","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1982","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"1983","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"1984","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"1985","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"1986","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"1987","EUCAST 2025","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"1988","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"1989","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"1990","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1991","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1992","EUCAST 2025","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"1993","EUCAST 2025","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"1994","EUCAST 2025","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1995","EUCAST 2025","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"1996","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"1997","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"1998","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"1999","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2000","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"2001","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2002","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2003","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2004","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2005","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"2006","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2007","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"2008","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2009","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2010","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2011","EUCAST 2025","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2012","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,NA
|
|
"2013","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2014","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2015","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2016","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2017","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2018","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2019","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2020","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2021","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",14,14,TRUE,FALSE,NA
|
|
"2022","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA
|
|
"2023","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"2024","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"2025","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2026","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2027","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"2028","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"2029","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"2030","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA
|
|
"2031","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2032","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2033","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2034","EUCAST 2025","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"2035","EUCAST 2025","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"2036","EUCAST 2025","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"2037","EUCAST 2025","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"2038","EUCAST 2025","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"2039","EUCAST 2025","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2040","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"2041","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2042","EUCAST 2025","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"2043","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"2044","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2045","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2046","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"2047","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2048","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2049","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"2050","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2051","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2052","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2053","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2054","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"2055","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"2056","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used."
|
|
"2057","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used."
|
|
"2058","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"2059","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2060","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2061","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2062","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"2063","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"2064","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"2065","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"2066","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2067","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2068","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2069","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems."
|
|
"2070","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2071","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"2072","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2073","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2074","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2075","EUCAST 2025","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"2076","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2077","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2078","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2079","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2080","EUCAST 2025","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"2081","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2082","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2083","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2084","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2085","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"2086","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
|
|
"2087","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"2088","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2089","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2090","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2091","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2092","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2093","EUCAST 2025","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"2094","EUCAST 2025","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"2095","EUCAST 2025","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"2096","EUCAST 2025","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 unit",26,26,FALSE,FALSE,NA
|
|
"2097","EUCAST 2025","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2098","EUCAST 2025","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"2099","EUCAST 2025","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"2100","EUCAST 2025","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
|
"2101","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"2102","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA
|
|
"2103","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"2104","EUCAST 2025","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"2105","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2106","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2107","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"2108","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"2109","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"2110","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2111","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2112","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2113","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2114","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"2115","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"2116","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,32,32,FALSE,FALSE,NA
|
|
"2117","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2118","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2119","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2120","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"2121","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2122","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2123","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2124","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2125","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2126","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2127","EUCAST 2025","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2128","EUCAST 2025","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2129","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2130","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2131","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1 unit",23,23,FALSE,FALSE,NA
|
|
"2132","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2133","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"2134","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2135","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2136","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"2137","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2138","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2139","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2140","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2141","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2142","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2143","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2144","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2145","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2146","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2147","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2148","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2149","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2150","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2151","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2152","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"2153","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2154","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"2155","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA
|
|
"2156","EUCAST 2025","human","human","DISK",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1 unit",18,18,FALSE,FALSE,NA
|
|
"2157","EUCAST 2025","human","human","MIC",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2158","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"2159","EUCAST 2025","human","human","DISK","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",22,19,FALSE,FALSE,NA
|
|
"2160","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2161","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2162","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2163","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2164","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2165","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2166","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"2167","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2168","EUCAST 2025","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"2169","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2170","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2171","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"2172","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"2173","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2174","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2175","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2176","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"2177","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2178","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"2179","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2180","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2181","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2182","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2183","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2184","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2185","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2186","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2187","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2188","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2189","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"2190","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2191","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"2192","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2193","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2194","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"2195","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2196","EUCAST 2025","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2197","EUCAST 2025","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2198","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2199","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2200","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2201","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2202","EUCAST 2025","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2203","EUCAST 2025","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2204","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2205","EUCAST 2025","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"2206","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,1,FALSE,FALSE,NA
|
|
"2207","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2208","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"2209","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2210","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2211","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2212","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2213","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2214","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2215","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2216","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2217","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2218","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2219","EUCAST 2025","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"2220","EUCAST 2025","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",21,21,FALSE,FALSE,NA
|
|
"2221","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"2222","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2223","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"2224","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2225","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"2226","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"2227","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"2228","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2229","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"2230","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2231","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"2232","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2233","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2234","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"2235","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2236","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2237","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"2238","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2239","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"2240","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2241","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2242","EUCAST 2025","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2243","EUCAST 2025","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,12,FALSE,FALSE,NA
|
|
"2244","EUCAST 2025","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,21,21,FALSE,FALSE,NA
|
|
"2245","EUCAST 2025","human","human","DISK","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,12,12,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2246","EUCAST 2025","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2247","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,1,FALSE,FALSE,NA
|
|
"2248","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2249","EUCAST 2025","human","human","MIC","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2250","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2251","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2252","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2253","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2254","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"2255","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2256","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"2257","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2258","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"2259","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2260","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"2261","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2262","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2263","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"2264","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"2265","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2266","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"2267","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2268","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"2269","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2270","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2271","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
|
|
"2272","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"2273","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2274","EUCAST 2025","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"2275","EUCAST 2025","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"2276","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2277","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2278","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2279","EUCAST 2025","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2280","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2281","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2282","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2283","EUCAST 2025","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2284","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2285","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"2286","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2287","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2288","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2289","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2290","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2291","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2292","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2293","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2294","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2295","EUCAST 2025","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2296","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"2297","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"2298","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/20 mcg",25,25,FALSE,FALSE,NA
|
|
"2299","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"2300","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"2301","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2302","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"2303","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2304","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"2305","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,TRUE,FALSE,NA
|
|
"2306","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"2307","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA
|
|
"2308","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"2309","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA
|
|
"2310","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"2311","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"2312","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test."
|
|
"2313","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2314","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"2315","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2316","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"2317","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,TRUE,FALSE,NA
|
|
"2318","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"2319","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2320","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"2321","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,NA
|
|
"2322","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2323","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2324","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"2325","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2326","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"2327","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"2328","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2329","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2330","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"2331","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"2332","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",22,22,FALSE,FALSE,"[7] See table of dosages for dosing for different indications."
|
|
"2333","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications."
|
|
"2334","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"2335","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2336","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"2337","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2338","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"2339","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2340","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"2341","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2342","EUCAST 2025","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"2343","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/20 mcg",22,22,FALSE,FALSE,NA
|
|
"2344","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L."
|
|
"2345","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2346","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2347","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2348","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2349","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2350","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2351","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"2352","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"2353","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"2354","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,NA
|
|
"2355","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"2356","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA
|
|
"2357","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"2358","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2359","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2360","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"2361","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"2362","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA
|
|
"2363","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2364","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",20,20,FALSE,FALSE,NA
|
|
"2365","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"2366","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"2367","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"2368","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"2369","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2370","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,TRUE,FALSE,NA
|
|
"2371","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"2372","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"2373","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"2374","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2375","EUCAST 2025","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
|
|
"2376","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2377","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"2378","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2379","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2380","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2381","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2382","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2383","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2384","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2385","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"2386","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2387","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"2388","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA
|
|
"2389","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2390","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"2391","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"2392","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2393","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2394","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2395","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"2396","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2397","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"2398","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2399","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2400","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2401","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"2402","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2403","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2404","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"2405","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2406","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2407","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"2408","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"2409","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2410","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2411","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"2412","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2413","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"2414","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"2415","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2416","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2417","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2418","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2419","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2420","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2421","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"2422","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,NA
|
|
"2423","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"2424","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"2425","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2426","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2427","EUCAST 2024","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"2428","EUCAST 2024","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"2429","EUCAST 2024","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA
|
|
"2430","EUCAST 2024","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2431","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2432","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2433","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2434","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2435","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2436","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"2437","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2438","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2439","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2440","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"2441","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2442","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"2443","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,NA
|
|
"2444","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"2445","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"2446","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2447","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"2448","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA
|
|
"2449","EUCAST 2024","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"2450","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"2451","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2452","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"2453","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2454","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"2455","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2456","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"2457","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2458","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"2459","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,NA
|
|
"2460","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"2461","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"2462","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2463","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"2464","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA
|
|
"2465","EUCAST 2024","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"2466","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"2467","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2468","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"2469","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2470","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"2471","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2472","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"2473","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2474","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"2475","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2476","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"2477","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"2478","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"2479","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"2480","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"2481","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"2482","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2483","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2484","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2485","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2486","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"2487","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2488","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"2489","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2490","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"2491","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2492","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"2493","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2494","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2495","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2496","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"2497","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2498","EUCAST 2024","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"2499","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"2500","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2501","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"2502","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"2503","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.25,FALSE,FALSE,NA
|
|
"2504","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"2505","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2506","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"2507","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"2508","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2509","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,NA
|
|
"2510","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2511","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,18,FALSE,FALSE,NA
|
|
"2512","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2513","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2514","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2515","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,NA
|
|
"2516","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2517","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2518","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2519","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",14,14,FALSE,FALSE,NA
|
|
"2520","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2521","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"2522","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2523","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2524","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2525","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"2526","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2527","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"2528","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2529","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"2530","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2531","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",25,25,FALSE,FALSE,NA
|
|
"2532","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"2533","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",24,24,FALSE,FALSE,NA
|
|
"2534","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2535","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,27,FALSE,FALSE,NA
|
|
"2536","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2537","EUCAST 2024","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2538","EUCAST 2024","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2539","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"2540","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2541","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2542","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,28,FALSE,FALSE,NA
|
|
"2543","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2544","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
|
|
"2545","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2546","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2547","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2548","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2549","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2550","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",42,42,FALSE,FALSE,NA
|
|
"2551","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2552","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"2553","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2554","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"2555","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2556","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"2557","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2558","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"2559","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"2560","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2561","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"2562","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2563","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2564","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2565","EUCAST 2024","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
|
|
"2566","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"2567","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2568","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"2569","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"2570","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"2571","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"2572","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"2573","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2574","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"2575","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"2576","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"2577","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"2578","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"2579","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"2580","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"2581","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"2582","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2583","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"2584","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"2585","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"2586","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2587","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"2588","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2589","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"2590","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2591","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"2592","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2593","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"2594","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2595","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"2596","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2597","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"2598","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"2599","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2600","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"2601","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"2602","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"2603","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"2604","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"2605","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"2606","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2607","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"2608","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2609","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"2610","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"2611","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"2612","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2613","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"2614","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2615","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2616","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2617","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"2618","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2619","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"2620","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"2621","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2622","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"2623","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
|
|
"2624","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
|
|
"2625","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"2626","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2627","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"2628","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2629","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"2630","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"2631","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA
|
|
"2632","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2633","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"2634","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2635","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2636","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2637","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"2638","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2639","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2640","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2641","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2642","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2643","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"2644","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2645","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"2646","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2647","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"2648","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2649","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2650","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2651","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2652","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",34,34,FALSE,FALSE,NA
|
|
"2653","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2654","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2655","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2656","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2657","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2658","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2659","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2660","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"2661","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2662","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2663","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"2664","EUCAST 2024","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"2665","EUCAST 2024","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2666","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2667","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2668","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2669","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2670","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2671","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"2672","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2673","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2674","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2675","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2676","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2677","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2678","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2679","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,NA
|
|
"2680","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2681","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2682","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2683","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2684","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"2685","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2686","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2687","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"2688","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2689","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2690","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"2691","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"2692","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",10,8,FALSE,FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"2693","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"2694","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"2695","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2696","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA
|
|
"2697","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"2698","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"2699","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"2700","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2701","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2702","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA
|
|
"2703","EUCAST 2024","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
|
|
"2704","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"2705","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"2706","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2707","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",24,24,FALSE,FALSE,NA
|
|
"2708","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2709","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,NA
|
|
"2710","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2711","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2712","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2713","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"2714","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2715","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"2716","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA
|
|
"2717","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2718","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2719","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"2720","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"2721","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2722","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA
|
|
"2723","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"2724","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"2725","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2726","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"2727","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2728","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"2729","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"2730","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"2731","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"2732","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2733","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"2734","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"2735","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA
|
|
"2736","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"2737","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA
|
|
"2738","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2739","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"2740","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"2741","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2742","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2743","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2744","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2745","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2746","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2747","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"2748","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2749","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2750","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2751","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2752","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2753","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2754","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2755","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"2756","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2757","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2758","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2759","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2760","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"2761","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2762","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2763","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2764","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2765","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2766","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2767","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2768","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2769","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2770","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2771","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2772","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2773","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"2774","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"2775","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"2776","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"2777","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2778","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2779","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"2780","EUCAST 2024","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"2781","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"2782","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2783","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2784","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2785","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2786","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2787","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2788","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2789","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2790","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2791","EUCAST 2024","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis."
|
|
"2792","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2793","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2794","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2795","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2796","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2797","EUCAST 2024","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis."
|
|
"2798","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2799","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2800","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2801","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2802","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2803","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"2804","EUCAST 2024","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
|
|
"2805","EUCAST 2024","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"2806","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2807","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2808","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2809","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2810","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2811","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2812","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2813","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2814","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2815","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2816","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2817","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2818","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2819","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2820","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2821","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2822","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2823","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2824","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2825","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2826","EUCAST 2024","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2827","EUCAST 2024","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2828","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2829","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2830","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2831","EUCAST 2024","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2832","EUCAST 2024","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"2833","EUCAST 2024","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2834","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"2835","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2836","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2837","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2838","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2839","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"2840","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"2841","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"2842","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"2843","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"2844","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"2845","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"2846","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2847","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"2848","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"2849","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"2850","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"2851","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2852","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"2853","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2854","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
|
|
"2855","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"2856","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2857","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"2858","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2859","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"2860","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2861","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"2862","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"2863","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"2864","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2865","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2866","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2867","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"2868","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2869","EUCAST 2024","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"2870","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"2871","EUCAST 2024","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2872","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA
|
|
"2873","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"2874","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"2875","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2876","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"2877","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2878","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"2879","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"2880","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2881","EUCAST 2024","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"2882","EUCAST 2024","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2883","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"2884","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2885","EUCAST 2024","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"2886","EUCAST 2024","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"2887","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2888","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2889","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"2890","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"2891","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2892","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"2893","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2894","EUCAST 2024","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"2895","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"2896","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2897","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2898","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2899","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2900","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"2901","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2902","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"2903","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"2904","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"2905","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"2906","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,NA
|
|
"2907","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"2908","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2909","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2910","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2911","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2912","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2913","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2914","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2915","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"2916","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2917","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2918","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2919","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2920","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2921","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2922","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2923","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2924","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2925","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2926","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2927","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2928","EUCAST 2024","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"2929","EUCAST 2024","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"2930","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"2931","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2932","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2933","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"2934","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"2935","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2936","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"2937","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2938","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"2939","EUCAST 2024","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
|
|
"2940","EUCAST 2024","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
|
|
"2941","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2942","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"2943","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2944","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"2945","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"2946","EUCAST 2024","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"2947","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,FALSE,FALSE,NA
|
|
"2948","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"2949","EUCAST 2024","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"2950","EUCAST 2024","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"2951","EUCAST 2024","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"2952","EUCAST 2024","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"2953","EUCAST 2024","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2954","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"2955","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
|
|
"2956","EUCAST 2024","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"2957","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2958","EUCAST 2024","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2959","EUCAST 2024","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"2960","EUCAST 2024","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"2961","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"2962","EUCAST 2024","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2963","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA
|
|
"2964","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2965","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"2966","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"2967","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"2968","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2969","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2970","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2971","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2972","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"2973","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"2974","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2975","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2976","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2977","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2978","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2979","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2980","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"2981","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"2982","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2983","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2984","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2985","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"2986","EUCAST 2024","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2987","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"2988","EUCAST 2024","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"2989","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA
|
|
"2990","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"2991","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"2992","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"2993","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"2994","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"2995","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"2996","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"2997","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"2998","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"2999","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"3000","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3001","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"3002","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"3003","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,18,FALSE,FALSE,NA
|
|
"3004","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"3005","EUCAST 2024","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"3006","EUCAST 2024","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA
|
|
"3007","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"3008","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"3009","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"3010","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3011","EUCAST 2024","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3012","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"3013","EUCAST 2024","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3014","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3015","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"3016","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3017","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"3018","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3019","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3020","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"3021","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"3022","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"3023","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications."
|
|
"3024","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"3025","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3026","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"3027","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3028","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"3029","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"3030","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"3031","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3032","EUCAST 2024","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,14,FALSE,FALSE,NA
|
|
"3033","EUCAST 2024","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"3034","EUCAST 2024","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA
|
|
"3035","EUCAST 2024","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3036","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",14,14,FALSE,FALSE,NA
|
|
"3037","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"3038","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3039","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"3040","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3041","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"3042","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3043","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3044","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3045","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"3046","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3047","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"3048","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3049","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3050","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"3051","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3052","EUCAST 2024","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3053","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"3054","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3055","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3056","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3057","EUCAST 2024","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"3058","EUCAST 2024","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"3059","EUCAST 2024","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3060","EUCAST 2024","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3061","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3062","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"3063","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"3064","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3065","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"3066","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3067","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3068","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3069","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3070","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"3071","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3072","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"3073","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3074","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3075","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3076","EUCAST 2024","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3077","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,NA
|
|
"3078","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3079","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3080","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3081","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3082","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3083","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3084","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3085","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3086","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",14,14,TRUE,FALSE,NA
|
|
"3087","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA
|
|
"3088","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"3089","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"3090","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3091","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3092","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"3093","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"3094","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"3095","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA
|
|
"3096","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3097","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3098","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3099","EUCAST 2024","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"3100","EUCAST 2024","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"3101","EUCAST 2024","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"3102","EUCAST 2024","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"3103","EUCAST 2024","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"3104","EUCAST 2024","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3105","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"3106","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3107","EUCAST 2024","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"3108","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"3109","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3110","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3111","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"3112","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3113","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3114","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"3115","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3116","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3117","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3118","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3119","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3120","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3121","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
|
|
ND = No ECOFF available."
|
|
"3122","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
|
|
ND = No ECOFF available."
|
|
"3123","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"3124","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3125","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3126","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3127","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"3128","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"3129","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"3130","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"3131","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3132","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3133","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3134","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin."
|
|
"3135","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3136","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"3137","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3138","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3139","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3140","EUCAST 2024","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"3141","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3142","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3143","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3144","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3145","EUCAST 2024","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"3146","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3147","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3148","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3149","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3150","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3151","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3152","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"3153","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3154","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3155","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3156","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3157","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3158","EUCAST 2024","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"3159","EUCAST 2024","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"3160","EUCAST 2024","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"3161","EUCAST 2024","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 unit",26,26,FALSE,FALSE,NA
|
|
"3162","EUCAST 2024","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3163","EUCAST 2024","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"3164","EUCAST 2024","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
|
"3165","EUCAST 2024","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
|
"3166","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"3167","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA
|
|
"3168","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"3169","EUCAST 2024","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"3170","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3171","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3172","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"3173","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"3174","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"3175","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3176","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3177","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3178","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3179","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"3180","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"3181","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,32,32,FALSE,FALSE,NA
|
|
"3182","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3183","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3184","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3185","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"3186","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3187","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3188","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3189","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3190","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3191","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3192","EUCAST 2024","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3193","EUCAST 2024","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3194","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3195","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3196","EUCAST 2024","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1 unit",18,18,FALSE,FALSE,NA
|
|
"3197","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3198","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"3199","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3200","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3201","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"3202","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3203","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3204","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3205","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3206","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3207","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3208","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3209","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3210","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3211","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3212","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3213","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3214","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3215","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3216","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3217","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"3218","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3219","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"3220","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA
|
|
"3221","EUCAST 2024","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1 unit",19,19,FALSE,FALSE,NA
|
|
"3222","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3223","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"3224","EUCAST 2024","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",22,19,FALSE,FALSE,NA
|
|
"3225","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3226","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3227","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3228","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3229","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3230","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3231","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"3232","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3233","EUCAST 2024","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"3234","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3235","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3236","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"3237","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"3238","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3239","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3240","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3241","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"3242","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3243","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"3244","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3245","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3246","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3247","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3248","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3249","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3250","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3251","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3252","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"3253","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3254","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"3255","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3256","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"3257","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3258","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3259","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"3260","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3261","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3262","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3263","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3264","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3265","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3266","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3267","EUCAST 2024","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3268","EUCAST 2024","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3269","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3270","EUCAST 2024","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"3271","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"3272","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3273","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"3274","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3275","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3276","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3277","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3278","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3279","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3280","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3281","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3282","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3283","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3284","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"3285","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"3286","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"3287","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"3288","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"3289","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"3290","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3291","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"3292","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3293","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"3294","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3295","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3296","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"3297","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3298","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3299","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"3300","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3301","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"3302","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3303","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3304","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,12,FALSE,FALSE,NA
|
|
"3305","EUCAST 2024","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3306","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,2,FALSE,FALSE,NA
|
|
"3307","EUCAST 2024","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3308","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3309","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3310","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3311","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3312","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"3313","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA
|
|
"3314","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"3315","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3316","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"3317","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3318","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"3319","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3320","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3321","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"3322","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"3323","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3324","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"3325","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3326","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"3327","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3328","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3329","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
|
|
"3330","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"3331","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3332","EUCAST 2024","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"3333","EUCAST 2024","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"3334","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3335","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3336","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3337","EUCAST 2024","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3338","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3339","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3340","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3341","EUCAST 2024","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3342","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3343","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"3344","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3345","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3346","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3347","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3348","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3349","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3350","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3351","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3352","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3353","EUCAST 2024","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3354","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"3355","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"3356","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"3357","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3358","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"3359","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"3360","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"3361","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,TRUE,FALSE,NA
|
|
"3362","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"3363","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA
|
|
"3364","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"3365","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA
|
|
"3366","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"3367","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"3368","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test."
|
|
"3369","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3370","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"3371","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3372","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"3373","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,TRUE,FALSE,NA
|
|
"3374","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"3375","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3376","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"3377","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,NA
|
|
"3378","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"3379","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3380","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"3381","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3382","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"3383","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"3384","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"3385","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA
|
|
"3386","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"3387","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"3388","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications."
|
|
"3389","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
|
|
"3390","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"3391","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA
|
|
"3392","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"3393","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3394","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"3395","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3396","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"3397","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA
|
|
"3398","EUCAST 2024","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"3399","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3400","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3401","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3402","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3403","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3404","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3405","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"3406","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"3407","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"3408","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,NA
|
|
"3409","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"3410","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA
|
|
"3411","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"3412","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3413","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3414","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"3415","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"3416","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA
|
|
"3417","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3418","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",20,20,FALSE,FALSE,NA
|
|
"3419","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"3420","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"3421","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents."
|
|
"3422","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"3423","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3424","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,TRUE,FALSE,NA
|
|
"3425","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"3426","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"3427","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"3428","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3429","EUCAST 2024","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
|
|
"3430","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3431","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"3432","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA
|
|
"3433","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3434","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3435","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3436","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3437","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3438","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3439","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"3440","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3441","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"3442","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA
|
|
"3443","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3444","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"3445","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"3446","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3447","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3448","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA
|
|
"3449","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"3450","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3451","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"3452","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"3453","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3454","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3455","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"3456","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3457","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3458","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"3459","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3460","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"3461","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"3462","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"3463","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3464","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3465","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"3466","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3467","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"3468","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"3469","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3470","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3471","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3472","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3473","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3474","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3475","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"3476","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"3477","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"3478","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,NA
|
|
"3479","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"3480","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"3481","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3482","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3483","EUCAST 2023","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"3484","EUCAST 2023","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"3485","EUCAST 2023","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA
|
|
"3486","EUCAST 2023","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3487","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3488","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3489","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3490","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3491","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3492","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"3493","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3494","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3495","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3496","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"3497","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3498","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"3499","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,NA
|
|
"3500","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"3501","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"3502","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3503","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"3504","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA
|
|
"3505","EUCAST 2023","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"3506","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,NA
|
|
"3507","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3508","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"3509","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3510","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"3511","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3512","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"3513","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3514","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"3515","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,NA
|
|
"3516","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"3517","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"3518","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3519","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"3520","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA
|
|
"3521","EUCAST 2023","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"3522","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,NA
|
|
"3523","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3524","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"3525","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3526","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"3527","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3528","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"3529","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"3530","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"3531","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"3532","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"3533","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"3534","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"3535","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"3536","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"3537","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"3538","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3539","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3540","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3541","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3542","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"3543","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3544","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"3545","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3546","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"3547","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3548","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"3549","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3550","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3551","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3552","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"3553","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3554","EUCAST 2023","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"3555","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"3556","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3557","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",14,14,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
|
|
"3558","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
|
|
"3559","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"3560","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3561","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3562","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3563","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"3564","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3565","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"3566","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3567","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"3568","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3569","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",25,25,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
|
|
"3570","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
|
|
"3571","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",24,24,FALSE,FALSE,NA
|
|
"3572","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3573","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"3574","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3575","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"3576","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3577","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"3578","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3579","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"3580","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"3581","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3582","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"3583","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3584","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3585","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3586","EUCAST 2023","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
|
|
"3587","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"3588","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3589","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"3590","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"3591","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3592","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3593","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"3594","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3595","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"3596","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
|
|
"3597","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3598","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3599","EUCAST 2023","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"3600","EUCAST 2023","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"3601","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"3602","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3603","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"3604","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"3605","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"3606","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3607","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"3608","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3609","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","1 unit",29,29,FALSE,FALSE,NA
|
|
"3610","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3611","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"3612","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3613","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"3614","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3615","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"3616","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3617","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"3618","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"3619","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3620","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"3621","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
|
|
"3622","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,15,FALSE,FALSE,"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
|
|
"3623","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
|
|
"3624","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3625","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"3626","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3627","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"3628","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3629","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"3630","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"3631","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1 unit",50,12,FALSE,FALSE,NA
|
|
"3632","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3633","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"3634","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3635","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3636","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3637","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"3638","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3639","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
|
|
"3640","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,NA
|
|
"3641","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"3642","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,15,FALSE,FALSE,"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
|
|
"3643","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
|
|
"3644","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline."
|
|
"3645","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"3646","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3647","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"3648","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3649","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"3650","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
|
|
"3651","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1 unit",50,12,FALSE,FALSE,NA
|
|
"3652","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3653","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,NA
|
|
"3654","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3655","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3656","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3657","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"3658","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3659","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3660","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3661","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3662","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3663","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"3664","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3665","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"3666","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3667","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
|
|
"3668","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3669","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3670","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3671","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3672","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",34,34,FALSE,FALSE,NA
|
|
"3673","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3674","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3675","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3676","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3677","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3678","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3679","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3680","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"3681","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3682","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3683","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"3684","EUCAST 2023","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"3685","EUCAST 2023","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3686","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3687","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3688","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3689","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3690","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3691","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"3692","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3693","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3694","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3695","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3696","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3697","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3698","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3699","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,NA
|
|
"3700","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3701","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3702","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3703","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3704","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"3705","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3706","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3707","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"3708","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3709","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3710","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"3711","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"3712","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",10,8,FALSE,FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"3713","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"3714","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"3715","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3716","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA
|
|
"3717","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"3718","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"3719","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"3720","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3721","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3722","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA
|
|
"3723","EUCAST 2023","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
|
|
"3724","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"3725","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"3726","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3727","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"3728","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3729","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",24,24,FALSE,FALSE,NA
|
|
"3730","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3731","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,NA
|
|
"3732","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3733","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3734","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3735","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"3736","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3737","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"3738","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA
|
|
"3739","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3740","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3741","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"3742","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"3743","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3744","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA
|
|
"3745","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"3746","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"3747","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3748","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"3749","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3750","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",24,24,TRUE,FALSE,"[E] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"3751","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"3752","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3753","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"3754","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"3755","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA
|
|
"3756","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"3757","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA
|
|
"3758","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3759","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"3760","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"3761","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"3762","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3763","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3764","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3765","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3766","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3767","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"3768","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3769","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3770","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3771","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3772","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3773","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3774","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3775","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"3776","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3777","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3778","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3779","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3780","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"3781","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3782","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3783","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3784","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3785","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3786","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"3787","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3788","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3789","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3790","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3791","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3792","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3793","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"3794","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"3795","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"3796","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"3797","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3798","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3799","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"3800","EUCAST 2023","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"3801","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"3802","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3803","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3804","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3805","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3806","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3807","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3808","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3809","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3810","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3811","EUCAST 2023","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3812","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3813","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3814","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3815","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3816","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3817","EUCAST 2023","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3818","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3819","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3820","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3821","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3822","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"3823","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"3824","EUCAST 2023","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
|
|
"3825","EUCAST 2023","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"3826","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3827","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3828","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3829","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3830","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3831","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3832","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3833","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3834","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3835","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3836","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3837","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3838","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3839","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3840","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3841","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3842","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3843","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3844","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3845","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3846","EUCAST 2023","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3847","EUCAST 2023","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3848","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3849","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3850","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3851","EUCAST 2023","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3852","EUCAST 2023","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"3853","EUCAST 2023","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3854","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"3855","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3856","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3857","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3858","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3859","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"3860","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"3861","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"3862","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"3863","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"3864","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"3865","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"3866","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3867","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"3868","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"3869","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3870","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"3871","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3872","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"3873","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3874","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
|
|
"3875","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"3876","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3877","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"3878","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3879","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"3880","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3881","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",25,25,FALSE,FALSE,NA
|
|
"3882","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"3883","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"3884","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3885","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3886","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3887","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"3888","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3889","EUCAST 2023","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"3890","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"3891","EUCAST 2023","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3892","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA
|
|
"3893","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"3894","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"3895","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3896","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"3897","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3898","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"3899","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"3900","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3901","EUCAST 2023","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"3902","EUCAST 2023","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3903","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"3904","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3905","EUCAST 2023","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","1 unit",13,13,FALSE,FALSE,NA
|
|
"3906","EUCAST 2023","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"3907","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3908","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3909","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"3910","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"3911","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3912","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"3913","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3914","EUCAST 2023","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"3915","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"3916","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3917","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3918","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3919","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3920","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"3921","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"3922","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"3923","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"3924","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"3925","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"3926","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,NA
|
|
"3927","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"3928","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3929","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3930","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3931","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3932","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3933","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3934","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3935","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"3936","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"3937","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3938","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3939","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3940","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3941","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3942","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3943","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3944","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3945","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3946","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3947","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3948","EUCAST 2023","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"3949","EUCAST 2023","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"3950","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"3951","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3952","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3953","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"3954","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"3955","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3956","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"3957","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3958","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"3959","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,NA
|
|
"3960","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3961","EUCAST 2023","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
|
|
"3962","EUCAST 2023","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"3963","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3964","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"3965","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3966","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"3967","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"3968","EUCAST 2023","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"3969","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,FALSE,FALSE,NA
|
|
"3970","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"3971","EUCAST 2023","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,1,FALSE,FALSE,NA
|
|
"3972","EUCAST 2023","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,1,FALSE,FALSE,NA
|
|
"3973","EUCAST 2023","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"3974","EUCAST 2023","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"3975","EUCAST 2023","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3976","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"3977","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
|
|
"3978","EUCAST 2023","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"3979","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3980","EUCAST 2023","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3981","EUCAST 2023","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"3982","EUCAST 2023","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"3983","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"3984","EUCAST 2023","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"3985","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA
|
|
"3986","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3987","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"3988","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone."
|
|
"3989","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"3990","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3991","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3992","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3993","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3994","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"3995","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"3996","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3997","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3998","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"3999","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4000","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4001","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4002","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"4003","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4004","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4005","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4006","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4007","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
|
"4008","EUCAST 2023","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4009","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"4010","EUCAST 2023","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4011","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA
|
|
"4012","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"4013","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4014","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"4015","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4016","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"4017","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4018","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"4019","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"4020","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4021","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"4022","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4023","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"4024","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA
|
|
"4025","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,18,FALSE,FALSE,NA
|
|
"4026","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4027","EUCAST 2023","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"4028","EUCAST 2023","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA
|
|
"4029","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"4030","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4031","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"4032","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4033","EUCAST 2023","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4034","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4035","EUCAST 2023","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4036","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4037","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"4038","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4039","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"4040","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4041","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4042","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"4043","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"4044","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"4045","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications."
|
|
"4046","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"4047","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4048","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"4049","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4050","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"4051","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"4052","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"4053","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4054","EUCAST 2023","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,14,FALSE,FALSE,NA
|
|
"4055","EUCAST 2023","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"4056","EUCAST 2023","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA
|
|
"4057","EUCAST 2023","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4058","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",14,14,FALSE,FALSE,NA
|
|
"4059","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"4060","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4061","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4062","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4063","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"4064","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4065","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4066","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4067","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"4068","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4069","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"4070","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4071","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4072","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"4073","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4074","EUCAST 2023","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4075","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","1 unit",17,17,FALSE,FALSE,NA
|
|
"4076","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4077","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4078","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4079","EUCAST 2023","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"4080","EUCAST 2023","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"4081","EUCAST 2023","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4082","EUCAST 2023","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4083","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4084","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"4085","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"4086","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4087","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"4088","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4089","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4090","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4091","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4092","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review."
|
|
"4093","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"4094","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4095","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"4096","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4097","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4098","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4099","EUCAST 2023","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4100","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,NA
|
|
"4101","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4102","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4103","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4104","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4105","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4106","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4107","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4108","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4109","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",14,14,TRUE,FALSE,NA
|
|
"4110","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA
|
|
"4111","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"4112","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"4113","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"4114","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"4115","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"4116","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"4117","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"4118","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA
|
|
"4119","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4120","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4121","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4122","EUCAST 2023","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"4123","EUCAST 2023","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"4124","EUCAST 2023","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"4125","EUCAST 2023","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"4126","EUCAST 2023","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"4127","EUCAST 2023","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4128","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"4129","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4130","EUCAST 2023","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"4131","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"4132","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4133","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4134","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4135","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4136","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4137","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"4138","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4139","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4140","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4141","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4142","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4143","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4144","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"4145","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"4146","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"4147","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4148","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4149","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4150","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"4151","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"4152","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"4153","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"4154","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4155","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4156","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4157","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin."
|
|
"4158","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4159","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4160","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4161","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4162","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4163","EUCAST 2023","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"4164","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"4165","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"4166","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4167","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4168","EUCAST 2023","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"4169","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4170","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4171","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4172","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4173","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4174","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4175","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"4176","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4177","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4178","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4179","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4180","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4181","EUCAST 2023","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"4182","EUCAST 2023","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
|
"4183","EUCAST 2023","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 unit",26,26,FALSE,FALSE,NA
|
|
"4184","EUCAST 2023","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4185","EUCAST 2023","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"4186","EUCAST 2023","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"4187","EUCAST 2023","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
|
"4188","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"4189","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA
|
|
"4190","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"4191","EUCAST 2023","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"4192","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4193","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4194","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"4195","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"4196","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"4197","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4198","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4199","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4200","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4201","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"4202","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"4203","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,NA
|
|
"4204","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4205","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4206","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4207","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4208","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4209","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4210","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4211","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4212","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4213","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4214","EUCAST 2023","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4215","EUCAST 2023","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4216","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4217","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4218","EUCAST 2023","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1 unit",18,18,FALSE,FALSE,NA
|
|
"4219","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4220","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"4221","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4222","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4223","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and"
|
|
"4224","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4225","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4226","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4227","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4228","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4229","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4230","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4231","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4232","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"4233","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4234","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4235","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4236","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4237","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4238","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4239","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4240","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4241","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"4242","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4243","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"4244","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA
|
|
"4245","EUCAST 2023","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1 unit",19,19,FALSE,FALSE,NA
|
|
"4246","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4247","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[3] Breakpoints for trimethoprim are currently under review."
|
|
"4248","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"4249","EUCAST 2023","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",22,19,FALSE,FALSE,NA
|
|
"4250","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4251","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4252","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4253","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4254","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4255","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4256","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"4257","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4258","EUCAST 2023","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"4259","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4260","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4261","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"4262","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"4263","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4264","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4265","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4266","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"4267","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4268","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"4269","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4270","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4271","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4272","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4273","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4274","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4275","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4276","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4277","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"4278","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4279","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"4280","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4281","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"4282","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4283","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4284","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4285","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4286","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4287","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4288","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4289","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4290","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4291","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4292","EUCAST 2023","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4293","EUCAST 2023","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4294","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4295","EUCAST 2023","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"4296","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"4297","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4298","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"4299","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4300","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4301","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4302","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4303","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4304","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
|
|
"4305","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4306","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4307","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,NA
|
|
"4308","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4309","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4310","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4311","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"4312","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"4313","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA
|
|
"4314","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"4315","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"4316","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"4317","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4318","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"4319","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4320","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"4321","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4322","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4323","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"4324","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4325","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4326","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"4327","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4328","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"4329","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4330","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4331","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,12,FALSE,FALSE,NA
|
|
"4332","EUCAST 2023","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4333","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,2,FALSE,FALSE,NA
|
|
"4334","EUCAST 2023","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4335","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4336","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4337","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4338","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4339","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"4340","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA
|
|
"4341","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"4342","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4343","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"4344","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4345","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"4346","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4347","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4348","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
|
"4349","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"4350","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4351","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"4352","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4353","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"4354","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4355","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4356","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
|
|
"4357","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"4358","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4359","EUCAST 2023","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"4360","EUCAST 2023","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"4361","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4362","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4363","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4364","EUCAST 2023","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4365","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4366","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4367","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4368","EUCAST 2023","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4369","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4370","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"4371","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4372","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4373","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4374","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4375","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4376","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4377","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4378","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4379","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4380","EUCAST 2023","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4381","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"4382","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"4383","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"4384","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4385","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"4386","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"4387","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"4388","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,TRUE,FALSE,NA
|
|
"4389","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"4390","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA
|
|
"4391","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"4392","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA
|
|
"4393","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"4394","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4395","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test."
|
|
"4396","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4397","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"4398","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4399","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"4400","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,TRUE,FALSE,NA
|
|
"4401","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"4402","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4403","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"4404","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,NA
|
|
"4405","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"4406","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4407","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"4408","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4409","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"4410","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"4411","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"4412","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA
|
|
"4413","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"4414","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"4415","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications."
|
|
"4416","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
|
|
"4417","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"4418","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA
|
|
"4419","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"4420","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4421","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"4422","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4423","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"4424","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA
|
|
"4425","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",21,21,FALSE,FALSE,"[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review."
|
|
"4426","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review."
|
|
"4427","EUCAST 2023","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"4428","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4429","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4430","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4431","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4432","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4433","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4434","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"4435","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"4436","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"4437","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,NA
|
|
"4438","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"4439","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA
|
|
"4440","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"4441","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4442","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4443","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"4444","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"4445","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA
|
|
"4446","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4447","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",20,20,FALSE,FALSE,NA
|
|
"4448","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"4449","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"4450","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4451","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"4452","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4453","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,TRUE,FALSE,NA
|
|
"4454","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"4455","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"4456","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4457","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4458","EUCAST 2023","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
|
|
"4459","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4460","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"4461","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA
|
|
"4462","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4463","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4464","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4465","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4466","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4467","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4468","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"4469","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4470","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"4471","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA
|
|
"4472","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4473","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"4474","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"4475","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4476","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4477","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA
|
|
"4478","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"4479","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4480","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"4481","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"4482","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4483","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4484","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"4485","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4486","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4487","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"4488","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4489","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"4490","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"4491","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"4492","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4493","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4494","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"4495","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4496","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"4497","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4498","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4499","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4500","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4501","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4502","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4503","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4504","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"4505","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"4506","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"4507","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,NA
|
|
"4508","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"4509","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"4510","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4511","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4512","EUCAST 2022","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"4513","EUCAST 2022","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"4514","EUCAST 2022","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA
|
|
"4515","EUCAST 2022","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4516","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4517","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4518","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4519","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4520","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4521","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"4522","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4523","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4524","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4525","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"4526","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4527","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"4528","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA
|
|
"4529","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"4530","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"4531","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4532","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"4533","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA
|
|
"4534","EUCAST 2022","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"4535","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"4536","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4537","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"4538","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4539","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"4540","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4541","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"4542","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4543","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note"
|
|
"4544","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA
|
|
"4545","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"4546","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"4547","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4548","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"4549","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA
|
|
"4550","EUCAST 2022","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"4551","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"4552","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4553","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"4554","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4555","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"4556","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4557","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"4558","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"4559","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"4560","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"4561","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"4562","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4563","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"4564","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"4565","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"4566","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4567","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4568","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4569","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4570","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4571","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"4572","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4573","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"4574","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4575","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"4576","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4577","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"4578","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4579","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4580","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4581","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"4582","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4583","EUCAST 2022","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"4584","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"4585","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4586","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",10,10,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"4587","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4588","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",28,28,FALSE,FALSE,"[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene."
|
|
"4589","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene."
|
|
"4590","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"4591","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4592","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"4593","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4594","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"4595","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4596","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"4597","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4598","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"4599","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4600","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4601","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"4602","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4603","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"4604","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4605","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4606","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4607","EUCAST 2022","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
|
|
"4608","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"4609","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4610","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"4611","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"4612","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"4613","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"4614","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"4615","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4616","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"4617","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"4618","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"4619","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"4620","EUCAST 2022","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"4621","EUCAST 2022","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"4622","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"4623","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4624","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"4625","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"4626","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"4627","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4628","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"4629","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4630","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","1 unit",29,29,FALSE,FALSE,NA
|
|
"4631","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4632","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,25,FALSE,FALSE,NA
|
|
"4633","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"4634","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"4635","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4636","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"4637","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4638","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"4639","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4640","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",28,28,FALSE,FALSE,NA
|
|
"4641","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4642","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",24,24,FALSE,FALSE,NA
|
|
"4643","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4644","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",27,27,FALSE,FALSE,NA
|
|
"4645","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4646","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"4647","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4648","EUCAST 2022","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"4649","EUCAST 2022","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4650","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"4651","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4652","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"4653","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4654","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,NA
|
|
"4655","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4656","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",15,15,FALSE,FALSE,NA
|
|
"4657","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4658","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",24,24,FALSE,FALSE,NA
|
|
"4659","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4660","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"4661","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4662","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"4663","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"4664","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"4665","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"4666","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4667","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA
|
|
"4668","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"4669","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"4670","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"4671","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4672","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4673","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA
|
|
"4674","EUCAST 2022","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
|
|
"4675","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"4676","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"4677","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4678","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"4679","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4680","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",24,24,FALSE,FALSE,NA
|
|
"4681","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4682","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,20,FALSE,FALSE,NA
|
|
"4683","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"4684","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4685","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4686","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"4687","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4688","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"4689","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA
|
|
"4690","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4691","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4692","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"4693","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"4694","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4695","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA
|
|
"4696","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"4697","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"4698","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4699","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"4700","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4701","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"4702","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"4703","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"4704","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA
|
|
"4705","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"4706","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA
|
|
"4707","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"4708","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4709","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"4710","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4711","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",30,30,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"4712","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4713","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",35,35,FALSE,FALSE,NA
|
|
"4714","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4715","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,NA
|
|
"4716","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4717","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"4718","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4719","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",32,32,FALSE,FALSE,NA
|
|
"4720","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4721","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4722","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4723","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4724","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"4725","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4726","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4727","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4728","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4729","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4730","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4731","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"4732","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"4733","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"4734","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"4735","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4736","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4737","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"4738","EUCAST 2022","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"4739","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"4740","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4741","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4742","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4743","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4744","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4745","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4746","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4747","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4748","EUCAST 2022","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC."
|
|
"4749","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4750","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4751","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4752","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4753","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4754","EUCAST 2022","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC."
|
|
"4755","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4756","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4757","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4758","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4759","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"4760","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"4761","EUCAST 2022","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
|
|
"4762","EUCAST 2022","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"4763","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4764","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4765","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4766","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4767","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4768","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4769","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4770","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4771","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4772","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4773","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4774","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4775","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4776","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4777","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4778","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4779","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4780","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4781","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4782","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4783","EUCAST 2022","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4784","EUCAST 2022","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4785","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4786","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4787","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4788","EUCAST 2022","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4789","EUCAST 2022","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"4790","EUCAST 2022","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4791","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"4792","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4793","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4794","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4795","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4796","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"4797","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"4798","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4799","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"4800","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"4801","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"4802","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"4803","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4804","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"4805","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"4806","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4807","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"4808","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4809","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"4810","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4811","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
|
|
"4812","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"4813","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4814","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"4815","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4816","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"4817","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4818","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"4819","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4820","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"4821","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4822","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4823","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4824","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"4825","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4826","EUCAST 2022","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"4827","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"4828","EUCAST 2022","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4829","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA
|
|
"4830","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"4831","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"4832","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"4833","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4834","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"4835","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4836","EUCAST 2022","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"4837","EUCAST 2022","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4838","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"4839","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4840","EUCAST 2022","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"4841","EUCAST 2022","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4842","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4843","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4844","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"4845","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4846","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"4847","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,18,FALSE,FALSE,NA
|
|
"4848","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4849","EUCAST 2022","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"4850","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4851","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4852","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4853","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4854","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"4855","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"4856","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"4857","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"4858","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"4859","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"4860","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"4861","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,NA
|
|
"4862","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"4863","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4864","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4865","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4866","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"4867","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4868","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4869","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4870","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"4871","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4872","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4873","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4874","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4875","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4876","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4877","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4878","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4879","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4880","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4881","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4882","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4883","EUCAST 2022","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"4884","EUCAST 2022","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"4885","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"4886","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4887","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4888","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"4889","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"4890","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4891","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"4892","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4893","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
|
|
"4894","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"4895","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"4896","EUCAST 2022","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
|
|
"4897","EUCAST 2022","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4898","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4899","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"4900","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4901","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"4902","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"4903","EUCAST 2022","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"4904","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,FALSE,FALSE,NA
|
|
"4905","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"4906","EUCAST 2022","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"4907","EUCAST 2022","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"4908","EUCAST 2022","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"4909","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4910","EUCAST 2022","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4911","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"4912","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"4913","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"4914","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4915","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4916","EUCAST 2022","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"4917","EUCAST 2022","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"4918","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"4919","EUCAST 2022","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4920","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA
|
|
"4921","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"4922","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4923","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",31,31,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
|
|
"4924","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4925","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",34,34,FALSE,FALSE,NA
|
|
"4926","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"4927","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"4928","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4929","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",20,20,FALSE,FALSE,NA
|
|
"4930","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4931","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"4932","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4933","EUCAST 2022","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4934","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"4935","EUCAST 2022","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4936","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA
|
|
"4937","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"4938","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4939","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"4940","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4941","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"4942","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"4943","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"4944","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"4945","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4946","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"4947","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"4948","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"4949","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"4950","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,18,FALSE,FALSE,NA
|
|
"4951","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"4952","EUCAST 2022","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"4953","EUCAST 2022","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA
|
|
"4954","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"4955","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4956","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"4957","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4958","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","75 mcg",50,18,FALSE,FALSE,NA
|
|
"4959","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"4960","EUCAST 2022","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4961","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4962","EUCAST 2022","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4963","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4964","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"4965","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"4966","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"4967","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"4968","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"4969","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"4970","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"4971","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"4972","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications."
|
|
"4973","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"4974","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"4975","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"4976","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"4977","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"4978","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"4979","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"4980","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4981","EUCAST 2022","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,14,FALSE,FALSE,NA
|
|
"4982","EUCAST 2022","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"4983","EUCAST 2022","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA
|
|
"4984","EUCAST 2022","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4985","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",14,14,FALSE,FALSE,NA
|
|
"4986","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"4987","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4988","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"4989","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"4990","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"4991","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"4992","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4993","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4994","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"4995","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"4996","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"4997","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"4998","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"4999","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"5000","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5001","EUCAST 2022","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5002","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"5003","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5004","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5005","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5006","EUCAST 2022","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"5007","EUCAST 2022","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"5008","EUCAST 2022","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"5009","EUCAST 2022","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5010","EUCAST 2022","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5011","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5012","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5013","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5014","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"5015","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"5016","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5017","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"5018","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5019","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5020","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,NA
|
|
"5021","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5022","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5023","EUCAST 2022","human","human","MIC","screen only","B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5024","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"5025","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5026","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5027","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"5028","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5029","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5030","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5031","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5032","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,NA
|
|
"5033","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5034","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"5035","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5036","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5037","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5038","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5039","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,19,FALSE,FALSE,NA
|
|
"5040","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5041","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5042","EUCAST 2022","human","human","MIC","screen only","B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5043","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5044","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5045","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",14,14,TRUE,FALSE,NA
|
|
"5046","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA
|
|
"5047","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"5048","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"5049","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5050","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5051","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"5052","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"5053","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"5054","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA
|
|
"5055","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5056","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5057","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5058","EUCAST 2022","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5059","EUCAST 2022","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5060","EUCAST 2022","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5061","EUCAST 2022","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5062","EUCAST 2022","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.016,0.016,FALSE,FALSE,NA
|
|
"5063","EUCAST 2022","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5064","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"5065","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5066","EUCAST 2022","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"5067","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5068","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5069","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5070","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"5071","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5072","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5073","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"5074","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5075","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5076","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5077","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5078","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5079","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5080","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"5081","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"5082","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"5083","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5084","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"5085","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5086","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin."
|
|
"5087","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"5088","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"5089","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5090","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5091","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin."
|
|
"5092","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5093","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"5094","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5095","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5096","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5097","EUCAST 2022","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"5098","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5099","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5100","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5101","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5102","EUCAST 2022","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"5103","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5104","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5105","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5106","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5107","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5108","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5109","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5110","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5111","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5112","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5113","EUCAST 2022","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"5114","EUCAST 2022","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"5115","EUCAST 2022","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 unit",26,26,FALSE,FALSE,NA
|
|
"5116","EUCAST 2022","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5117","EUCAST 2022","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"5118","EUCAST 2022","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
|
"5119","EUCAST 2022","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
|
"5120","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"5121","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA
|
|
"5122","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5123","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5124","EUCAST 2022","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"5125","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5126","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5127","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5128","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"5129","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"5130","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5131","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5132","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5133","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5134","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5135","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5136","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5137","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,NA
|
|
"5138","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5139","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5140","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5141","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"5142","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5143","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5144","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5145","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5146","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5147","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5148","EUCAST 2022","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5149","EUCAST 2022","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"5150","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5151","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5152","EUCAST 2022","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,18,FALSE,FALSE,NA
|
|
"5153","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5154","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"5155","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5156","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5157","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5158","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5159","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5160","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,20,FALSE,FALSE,NA
|
|
"5161","EUCAST 2022","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5162","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5163","EUCAST 2022","human","human","MIC","screen only","B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5164","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5165","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5166","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5167","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5168","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,17,FALSE,FALSE,NA
|
|
"5169","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5170","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5171","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5172","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5173","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5174","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5175","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5176","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5177","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"5178","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5179","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"5180","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA
|
|
"5181","EUCAST 2022","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1 unit",19,19,FALSE,FALSE,NA
|
|
"5182","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5183","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA
|
|
"5184","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"5185","EUCAST 2022","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",22,19,FALSE,FALSE,NA
|
|
"5186","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5187","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5188","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5189","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5190","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5191","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5192","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"5193","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"5194","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5195","EUCAST 2022","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"5196","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5197","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5198","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5199","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"5200","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"5201","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5202","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5203","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5204","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"5205","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5206","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"5207","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5208","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5209","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5210","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5211","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5212","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5213","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5214","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5215","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5216","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5217","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"5218","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5219","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"5220","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5221","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5222","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"5223","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5224","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5225","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5226","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5227","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5228","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5229","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5230","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5231","EUCAST 2022","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"5232","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5233","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"5234","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"5235","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5236","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"5237","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5238","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5239","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5240","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5241","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"5242","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5243","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5244","EUCAST 2022","human","human","MIC","screen only","B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5245","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5246","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5247","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"5248","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5249","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5250","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5251","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"5252","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"5253","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"5254","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"5255","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"5256","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"5257","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5258","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"5259","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5260","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"5261","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5262","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5263","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"5264","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5265","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5266","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"5267","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5268","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"5269","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5270","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5271","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,12,FALSE,FALSE,NA
|
|
"5272","EUCAST 2022","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,18,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5273","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,2,FALSE,FALSE,NA
|
|
"5274","EUCAST 2022","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
|
|
"5275","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5276","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5277","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5278","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5279","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test."
|
|
"5280","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5281","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"5282","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5283","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"5284","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5285","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"5286","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5287","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5288","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",12,12,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test."
|
|
"5289","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"5290","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5291","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5292","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5293","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
|
|
"5294","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,18,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5295","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5296","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
|
|
"5297","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"5298","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5299","EUCAST 2022","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"5300","EUCAST 2022","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"5301","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5302","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"5303","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5304","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5305","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5306","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"5307","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5308","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5309","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5310","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5311","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5312","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"5313","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"5314","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"5315","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5316","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"5317","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5318","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"5319","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,TRUE,FALSE,NA
|
|
"5320","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"5321","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA
|
|
"5322","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5323","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"5324","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5325","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA
|
|
"5326","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"5327","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5328","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5329","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"5330","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5331","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"5332","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,TRUE,FALSE,NA
|
|
"5333","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"5334","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5335","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"5336","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,NA
|
|
"5337","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5338","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5339","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"5340","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5341","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"5342","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"5343","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5344","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5345","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"5346","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"5347","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications."
|
|
"5348","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
|
|
"5349","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"5350","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5351","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"5352","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5353","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"5354","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5355","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"5356","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5357","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",21,21,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"5358","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"5359","EUCAST 2022","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"5360","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5361","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5362","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5363","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5364","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5365","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5366","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"5367","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"5368","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"5369","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,NA
|
|
"5370","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"5371","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA
|
|
"5372","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"5373","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5374","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5375","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"5376","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"5377","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA
|
|
"5378","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5379","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",20,20,FALSE,FALSE,NA
|
|
"5380","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"5381","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"5382","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5383","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"5384","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5385","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,TRUE,FALSE,NA
|
|
"5386","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"5387","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"5388","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5389","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5390","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
|
|
"5391","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"5392","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5393","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5394","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"5395","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5396","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5397","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"5398","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5399","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","75 mcg",23,20,FALSE,FALSE,NA
|
|
"5400","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,16,FALSE,FALSE,NA
|
|
"5401","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"5402","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA
|
|
"5403","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5404","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"5405","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"5406","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
|
|
"5407","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5408","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5409","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"5410","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5411","EUCAST 2022","human","human","DISK","uncomplicated UTI only","UNKNOWN",6,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5412","EUCAST 2022","human","human","MIC","uncomplicated UTI only","UNKNOWN",6,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5413","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,20,FALSE,FALSE,NA
|
|
"5414","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5415","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5416","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5417","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",26,26,FALSE,FALSE,NA
|
|
"5418","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5419","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5420","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"5421","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5422","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5423","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"5424","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"5425","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5426","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5427","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"5428","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5429","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"5430","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"5431","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5432","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5433","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5434","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5435","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5436","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5437","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"5438","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"5439","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"5440","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA
|
|
"5441","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"5442","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"5443","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5444","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5445","EUCAST 2021","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"5446","EUCAST 2021","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"5447","EUCAST 2021","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA
|
|
"5448","EUCAST 2021","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5449","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5450","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5451","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5452","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5453","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5454","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"5455","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5456","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5457","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5458","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"5459","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5460","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"5461","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA
|
|
"5462","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"5463","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"5464","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5465","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"5466","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA
|
|
"5467","EUCAST 2021","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"5468","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"5469","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5470","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"5471","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5472","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"5473","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5474","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"5475","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5476","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"5477","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA
|
|
"5478","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"5479","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"5480","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5481","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"5482","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA
|
|
"5483","EUCAST 2021","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"5484","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"5485","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5486","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"5487","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5488","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"5489","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5490","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"5491","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5492","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"5493","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5494","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"5495","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5496","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"5497","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5498","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"5499","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5500","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5501","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5502","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5503","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"5504","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",17,17,FALSE,FALSE,NA
|
|
"5505","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5506","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",24,24,FALSE,FALSE,NA
|
|
"5507","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5508","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"5509","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5510","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"5511","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5512","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5513","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5514","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"5515","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5516","EUCAST 2021","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin."
|
|
"5517","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"5518","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5519","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"5520","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5521","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"5522","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5523","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"5524","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5525","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"5526","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"5527","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5528","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5529","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5530","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5531","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5532","EUCAST 2021","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,23,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
|
|
"5533","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"5534","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"5535","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"5536","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"5537","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"5538","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"5539","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"5540","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"5541","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"5542","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"5543","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"5544","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"5545","EUCAST 2021","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"5546","EUCAST 2021","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"5547","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,25,FALSE,FALSE,NA
|
|
"5548","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5549","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"5550","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"5551","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"5552","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5553","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"5554","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5555","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","1 unit",29,29,FALSE,FALSE,NA
|
|
"5556","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5557","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,25,FALSE,FALSE,NA
|
|
"5558","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"5559","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"5560","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5561","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"5562","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5563","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5564","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5565","EUCAST 2021","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"5566","EUCAST 2021","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5567","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5568","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5569","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"5570","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"5571","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"5572","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"5573","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5574","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA
|
|
"5575","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"5576","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"5577","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"5578","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5579","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5580","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA
|
|
"5581","EUCAST 2021","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B."
|
|
"5582","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
|
|
"5583","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"5584","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5585","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"5586","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5587","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",24,24,FALSE,FALSE,NA
|
|
"5588","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5589","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,20,FALSE,FALSE,NA
|
|
"5590","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"5591","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,22,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5592","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5593","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"5594","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5595","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"5596","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA
|
|
"5597","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5598","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5599","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"5600","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"5601","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5602","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA
|
|
"5603","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"5604","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"5605","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5606","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"5607","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5608","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"5609","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"5610","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5611","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5612","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"5613","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA
|
|
"5614","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"5615","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA
|
|
"5616","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5617","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5618","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"5619","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5620","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5621","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5622","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5623","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5624","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5625","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"DOR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5626","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5627","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"IMR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
|
|
"5628","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA
|
|
"5629","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA
|
|
"5630","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5631","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5632","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5633","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"5634","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5635","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5636","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5637","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5638","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5639","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5640","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5641","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5642","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"DOR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5643","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5644","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"IMR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"5645","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA
|
|
"5646","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA
|
|
"5647","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5648","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5649","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5650","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"5651","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5652","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"5653","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5654","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5655","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5656","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5657","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5658","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5659","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5660","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5661","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5662","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5663","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5664","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5665","EUCAST 2021","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"5666","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"5667","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"5668","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"5669","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5670","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5671","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5672","EUCAST 2021","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"5673","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5674","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5675","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5676","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5677","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5678","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5679","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5680","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5681","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis."
|
|
"5682","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[4] The breakpoints also apply to meningitis."
|
|
"5683","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5684","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5685","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis."
|
|
"5686","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[4] The breakpoints also apply to meningitis."
|
|
"5687","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5688","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5689","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5690","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5691","EUCAST 2021","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
|
|
"5692","EUCAST 2021","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"5693","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",23,23,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5694","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below."
|
|
"5695","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5696","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5697","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5698","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5699","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5700","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5701","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5702","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5703","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5704","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5705","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5706","EUCAST 2021","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5707","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5708","EUCAST 2021","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5709","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5710","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5711","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5712","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5713","EUCAST 2021","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"5714","EUCAST 2021","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"5715","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5716","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5717","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5718","EUCAST 2021","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5719","EUCAST 2021","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"5720","EUCAST 2021","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5721","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
|
|
"5722","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5723","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5724","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5725","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5726","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5727","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"5728","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5729","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"5730","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"5731","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"5732","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"5733","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5734","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"5735","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"5736","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5737","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"5738","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5739","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"5740","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5741","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5742","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"5743","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5744","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"5745","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5746","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"5747","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5748","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"5749","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5750","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"5751","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5752","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5753","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5754","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"5755","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5756","EUCAST 2021","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"5757","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"5758","EUCAST 2021","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5759","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA
|
|
"5760","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"5761","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin."
|
|
"5762","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5763","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5764","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5765","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5766","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"5767","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5768","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"5769","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5770","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"5771","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5772","EUCAST 2021","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"5773","EUCAST 2021","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5774","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5775","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5776","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"5777","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5778","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5779","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,18,FALSE,FALSE,NA
|
|
"5780","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5781","EUCAST 2021","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",31,31,FALSE,FALSE,NA
|
|
"5782","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5783","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5784","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5785","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5786","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5787","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"5788","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5789","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"5790","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5791","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"5792","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"5793","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,NA
|
|
"5794","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"5795","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5796","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5797","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5798","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5799","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5800","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5801","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5802","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"5803","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5804","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5805","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5806","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5807","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5808","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5809","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5810","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5811","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5812","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5813","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5814","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5815","EUCAST 2021","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"5816","EUCAST 2021","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"5817","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5818","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5819","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5820","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5821","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"5822","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5823","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5824","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5825","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5826","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"5827","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"5828","EUCAST 2021","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
|
|
"5829","EUCAST 2021","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5830","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5831","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"5832","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5833","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"5834","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"5835","EUCAST 2021","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"5836","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,FALSE,FALSE,NA
|
|
"5837","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"5838","EUCAST 2021","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"5839","EUCAST 2021","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"5840","EUCAST 2021","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"5841","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
|
|
"5842","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5843","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5844","EUCAST 2021","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections."
|
|
"5845","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"5846","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5847","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines)."
|
|
"5848","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"5849","EUCAST 2021","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"5850","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"5851","EUCAST 2021","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5852","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA
|
|
"5853","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5854","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"5855","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone."
|
|
"5856","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5857","EUCAST 2021","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5858","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"5859","EUCAST 2021","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5860","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA
|
|
"5861","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"5862","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5863","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"5864","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5865","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"5866","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"5867","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"5868","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,22,FALSE,FALSE,NA
|
|
"5869","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"5870","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"5871","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"5872","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"5873","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"5874","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,22,FALSE,FALSE,NA
|
|
"5875","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5876","EUCAST 2021","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"5877","EUCAST 2021","human","human","DISK","meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5878","EUCAST 2021","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA
|
|
"5879","EUCAST 2021","human","human","MIC","meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5880","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"5881","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5882","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"5883","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5884","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","75 mcg",50,18,FALSE,FALSE,NA
|
|
"5885","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"5886","EUCAST 2021","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5887","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"5888","EUCAST 2021","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5889","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5890","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"5891","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"5892","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"5893","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5894","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5895","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"5896","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"5897","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications."
|
|
"5898","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications."
|
|
"5899","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"5900","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
|
|
"5901","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"5902","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5903","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"5904","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"5905","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"5906","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5907","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"5908","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5909","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"5910","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5911","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"5912","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"5913","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5914","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5915","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"5916","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5917","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"5918","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"5919","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5920","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"5921","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"5922","EUCAST 2021","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"5923","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"5924","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5925","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5926","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5927","EUCAST 2021","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test."
|
|
"5928","EUCAST 2021","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"5929","EUCAST 2021","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"5930","EUCAST 2021","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5931","EUCAST 2021","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5932","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5933","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"5934","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"5935","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",22,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"5936","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""."
|
|
"5937","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5938","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5939","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5940","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5941","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5942","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5943","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"5944","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5945","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5946","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,NA
|
|
"5947","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"5948","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5949","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5950","EUCAST 2021","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"5951","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,NA
|
|
"5952","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"5953","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,23,FALSE,FALSE,NA
|
|
"5954","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"5955","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"5956","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5957","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"5958","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,19,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5959","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"5960","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5961","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"5962","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",14,14,TRUE,FALSE,NA
|
|
"5963","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA
|
|
"5964","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"5965","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
|
|
"5966","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5967","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"5968","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"5969","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
|
|
"5970","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"5971","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA
|
|
"5972","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5973","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5974","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"5975","EUCAST 2021","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5976","EUCAST 2021","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5977","EUCAST 2021","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5978","EUCAST 2021","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
|
|
"5979","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5980","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
|
|
"5981","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5982","EUCAST 2021","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"5983","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"5984","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5985","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5986","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"5987","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"5988","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"5989","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"5990","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5991","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5992","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"5993","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"5994","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"5995","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"5996","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"5997","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"5998","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"5999","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6000","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6001","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6002","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6003","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
|
|
"6004","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
|
|
"6005","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6006","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6007","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6008","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6009","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"6010","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6011","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6012","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6013","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"6014","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
|
|
"6015","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6016","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"6017","EUCAST 2021","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"6018","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6019","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6020","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6021","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"6022","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6023","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6024","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6025","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6026","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6027","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6028","EUCAST 2021","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm."
|
|
"6029","EUCAST 2021","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 unit",26,26,FALSE,FALSE,NA
|
|
"6030","EUCAST 2021","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6031","EUCAST 2021","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
|
|
"6032","EUCAST 2021","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
|
|
"6033","EUCAST 2021","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
|
|
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
|
|
"6034","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",13,13,TRUE,FALSE,NA
|
|
"6035","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA
|
|
"6036","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6037","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"6038","EUCAST 2021","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"6039","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6040","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6041","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6042","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"6043","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"6044","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6045","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6046","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6047","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6048","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6049","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6050","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6051","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,NA
|
|
"6052","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",19,19,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6053","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6054","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6055","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"6056","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6057","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6058","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6059","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6060","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6061","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6062","EUCAST 2021","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"6063","EUCAST 2021","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6064","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6065","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6066","EUCAST 2021","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6067","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6068","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,15,FALSE,FALSE,NA
|
|
"6069","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"6070","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6071","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6072","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6073","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6074","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6075","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6076","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6077","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6078","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6079","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6080","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,17,FALSE,FALSE,NA
|
|
"6081","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6082","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6083","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6084","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6085","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6086","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6087","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6088","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6089","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"6090","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6091","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"6092","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA
|
|
"6093","EUCAST 2021","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1 unit",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6094","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6095","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA
|
|
"6096","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"6097","EUCAST 2021","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6098","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6099","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6100","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6101","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6102","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6103","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6104","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"6105","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"6106","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"6107","EUCAST 2021","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"6108","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages."
|
|
"6109","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6110","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6111","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6112","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6113","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6114","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6115","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6116","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6117","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6118","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6119","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6120","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6121","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6122","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6123","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6124","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6125","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6126","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6127","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6128","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6129","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",12,12,FALSE,FALSE,NA
|
|
"6130","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6131","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"6132","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6133","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6134","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"6135","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6136","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6137","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6138","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6139","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6140","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6141","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6142","EUCAST 2021","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"6143","EUCAST 2021","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6144","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6145","EUCAST 2021","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,NA,FALSE,FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below."
|
|
"6146","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"6147","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6148","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,17,FALSE,FALSE,NA
|
|
"6149","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.5,FALSE,FALSE,NA
|
|
"6150","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6151","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6152","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6153","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6154","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6155","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6156","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6157","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"6158","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6159","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6160","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6161","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"6162","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6163","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6164","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6165","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6166","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"6167","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6168","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"6169","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6170","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"6171","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6172","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6173","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"6174","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6175","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6176","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
|
|
"6177","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6178","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"6179","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6180","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6181","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,12,FALSE,FALSE,NA
|
|
"6182","EUCAST 2021","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
|
|
"6183","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,2,FALSE,FALSE,NA
|
|
"6184","EUCAST 2021","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,NA,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
|
|
"6185","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6186","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6187","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6188","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6189","EUCAST 2021","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6190","EUCAST 2021","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6191","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6192","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"6193","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6194","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6195","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6196","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"6197","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6198","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6199","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6200","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6201","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6202","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"6203","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"6204","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"6205","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6206","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"6207","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6208","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"6209","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,TRUE,FALSE,NA
|
|
"6210","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"6211","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6212","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"6213","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"6214","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6215","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA
|
|
"6216","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"6217","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6218","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6219","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"6220","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6221","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"6222","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,TRUE,FALSE,NA
|
|
"6223","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"6224","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6225","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"6226","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,NA
|
|
"6227","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6228","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6229","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"6230","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6231","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"6232","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"6233","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6234","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6235","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"6236","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"6237","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications."
|
|
"6238","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
|
|
"6239","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"6240","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6241","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"6242","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6243","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,NA
|
|
"6244","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
|
|
"6245","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"6246","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6247","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",21,21,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"6248","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"6249","EUCAST 2021","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"6250","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6251","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6252","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6253","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6254","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6255","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6256","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",22,22,FALSE,FALSE,NA
|
|
"6257","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6258","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"6259","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA
|
|
"6260","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"6261","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6262","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"6263","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6264","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6265","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"6266","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"6267","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA
|
|
"6268","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6269","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"6270","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"6271","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6272","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"6273","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6274","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,TRUE,FALSE,NA
|
|
"6275","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"6276","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"6277","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6278","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6279","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6280","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"6281","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6282","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6283","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6284","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6285","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6286","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"6287","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6288","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","75 mcg",23,20,FALSE,FALSE,NA
|
|
"6289","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,NA
|
|
"6290","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"6291","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA
|
|
"6292","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6293","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"6294","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"6295","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6296","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6297","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6298","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",20,20,FALSE,FALSE,NA
|
|
"6299","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"6300","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6301","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"6302","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6303","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6304","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"6305","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,FALSE,FALSE,NA
|
|
"6306","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"6307","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6308","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"6309","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6310","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6311","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6312","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6313","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6314","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6315","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6316","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6317","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"6318","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA
|
|
"6319","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"6320","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"6321","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6322","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6323","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"6324","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA
|
|
"6325","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6326","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6327","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6328","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6329","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6330","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6331","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6332","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6333","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6334","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"6335","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6336","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"6337","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA
|
|
"6338","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"6339","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"6340","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6341","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"6342","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6343","EUCAST 2020","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"6344","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"6345","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6346","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"6347","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6348","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"6349","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6350","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"6351","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6352","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"6353","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA
|
|
"6354","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"6355","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"6356","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6357","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"6358","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6359","EUCAST 2020","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"6360","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"6361","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6362","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"6363","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6364","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"6365","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6366","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"6367","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6368","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"6369","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6370","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"6371","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6372","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"6373","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6374","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"6375","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6376","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6377","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6378","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",50,22,FALSE,FALSE,NA
|
|
"6379","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6380","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,18,FALSE,FALSE,NA
|
|
"6381","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6382","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,22,FALSE,FALSE,NA
|
|
"6383","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6384","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"6385","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,NA
|
|
"6386","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6387","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"6388","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6389","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6390","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6391","EUCAST 2020","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,23,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
|
|
"6392","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"6393","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6394","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"6395","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"6396","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"6397","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"6398","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"6399","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6400","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"6401","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"6402","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"6403","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"6404","EUCAST 2020","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"6405","EUCAST 2020","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"6406","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"6407","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6408","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"6409","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
|
|
"6410","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"6411","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6412","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"6413","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6414","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","1 unit",29,29,FALSE,FALSE,NA
|
|
"6415","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6416","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,25,FALSE,FALSE,NA
|
|
"6417","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"6418","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"6419","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6420","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"6421","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6422","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone."
|
|
"6423","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"6424","EUCAST 2020","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"6425","EUCAST 2020","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6426","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone."
|
|
"6427","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"6428","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
|
|
"6429","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
|
|
"6430","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
|
|
"6431","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
|
|
"6432","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6433","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA
|
|
"6434","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,21,FALSE,FALSE,NA
|
|
"6435","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"6436","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"6437","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6438","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6439","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA
|
|
"6440","EUCAST 2020","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
|
|
"6441","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
|
|
"6442","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"6443","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6444","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"6445","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6446","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",24,24,FALSE,FALSE,NA
|
|
"6447","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6448","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,20,FALSE,FALSE,NA
|
|
"6449","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6450","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,22,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6451","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6452","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",22,22,FALSE,FALSE,NA
|
|
"6453","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6454","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"6455","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA
|
|
"6456","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6457","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6458","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"6459","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"6460","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6461","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA
|
|
"6462","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"6463","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6464","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"6465","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6466","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone."
|
|
"6467","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"6468","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"6469","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA
|
|
"6470","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"6471","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6472","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
|
|
"6473","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6474","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6475","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6476","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6477","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6478","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6479","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6480","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"IMR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6481","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA
|
|
"6482","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA
|
|
"6483","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6484","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6485","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6486","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"6487","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6488","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6489","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"6490","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6491","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6492","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6493","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6494","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6495","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6496","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"IMR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6497","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA
|
|
"6498","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA
|
|
"6499","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6500","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6501","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6502","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"6503","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6504","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"6505","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"6506","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6507","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6508","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6509","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6510","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6511","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6512","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6513","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6514","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6515","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6516","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6517","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"6518","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"6519","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"6520","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"6521","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6522","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6523","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"6524","EUCAST 2020","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"6525","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6526","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6527","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6528","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6529","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6530","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6531","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6532","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6533","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6534","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6535","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6536","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6537","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6538","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6539","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6540","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6541","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6542","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"6543","EUCAST 2020","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"6544","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6545","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6546","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6547","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6548","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6549","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6550","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6551","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6552","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6553","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6554","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6555","EUCAST 2020","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6556","EUCAST 2020","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6557","EUCAST 2020","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6558","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6559","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6560","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6561","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6562","EUCAST 2020","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"6563","EUCAST 2020","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6564","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6565","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6566","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6567","EUCAST 2020","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6568","EUCAST 2020","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"6569","EUCAST 2020","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6570","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"6571","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6572","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6573","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6574","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6575","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6576","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
|
|
"6577","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"6578","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"6579","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"6580","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"6581","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"6582","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6583","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"6584","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"6585","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6586","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"6587","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6588","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"6589","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6590","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6591","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"6592","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6593","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"6594","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6595","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"6596","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6597","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"6598","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6599","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"6600","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6601","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6602","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6603","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"6604","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6605","EUCAST 2020","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"6606","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"6607","EUCAST 2020","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6608","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA
|
|
"6609","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"6610","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone."
|
|
"6611","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"6612","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"6613","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6614","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"6615","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6616","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"6617","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6618","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"6619","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6620","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6621","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6622","EUCAST 2020","human","human","DISK",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6623","EUCAST 2020","human","human","MIC",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6624","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"6625","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6626","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6627","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,18,FALSE,FALSE,NA
|
|
"6628","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6629","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Breakpoints relate to topical use only."
|
|
"6630","EUCAST 2020","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"6631","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Breakpoints relate to topical use only."
|
|
"6632","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6633","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6634","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6635","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6636","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6637","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"6638","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6639","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"6640","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6641","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"6642","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"6643","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,NA
|
|
"6644","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"6645","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6646","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6647","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6648","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6649","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6650","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"6651","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6652","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6653","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6654","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6655","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6656","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6657","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6658","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6659","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6660","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6661","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6662","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6663","EUCAST 2020","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"6664","EUCAST 2020","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6665","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6666","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6667","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6668","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6669","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"6670","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6671","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6672","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6673","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6674","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"6675","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6676","EUCAST 2020","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
|
|
"6677","EUCAST 2020","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6678","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6679","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"6680","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6681","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6682","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"6683","EUCAST 2020","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
|
|
"6684","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,FALSE,FALSE,NA
|
|
"6685","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6686","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"6687","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"6688","EUCAST 2020","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] See table of dosages."
|
|
"6689","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
|
|
"6690","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6691","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6692","EUCAST 2020","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6693","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"6694","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.25,FALSE,FALSE,NA
|
|
"6695","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines)."
|
|
"6696","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"6697","EUCAST 2020","human","human","DISK",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6698","EUCAST 2020","human","human","MIC",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6699","EUCAST 2020","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA
|
|
"6700","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"6701","EUCAST 2020","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6702","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA
|
|
"6703","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone."
|
|
"6704","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"6705","EUCAST 2020","human","human","DISK",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6706","EUCAST 2020","human","human","MIC",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"6707","EUCAST 2020","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6708","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,NA
|
|
"6709","EUCAST 2020","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6710","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA
|
|
"6711","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"6712","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"6713","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,NA
|
|
"6714","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6715","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,26,FALSE,FALSE,NA
|
|
"6716","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"6717","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"6718","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"6719","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA
|
|
"6720","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,20,FALSE,FALSE,NA
|
|
"6721","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA
|
|
"6722","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,22,FALSE,FALSE,NA
|
|
"6723","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA
|
|
"6724","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"6725","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA
|
|
"6726","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,18,FALSE,FALSE,NA
|
|
"6727","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"6728","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","75/10 mcg",50,18,FALSE,FALSE,NA
|
|
"6729","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6730","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","75 mcg",50,18,FALSE,FALSE,NA
|
|
"6731","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA
|
|
"6732","EUCAST 2020","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6733","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"6734","EUCAST 2020","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6735","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6736","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",50,18,FALSE,FALSE,NA
|
|
"6737","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"6738","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"6739","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6740","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6741","EUCAST 2020","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"6742","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"6743","EUCAST 2020","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30/10 mcg",24,24,FALSE,FALSE,"[2] See table of dosages for dosing for different indications."
|
|
"6744","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications."
|
|
"6745","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"6746","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6747","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6748","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"6749","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6750","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"6751","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6752","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"6753","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6754","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"6755","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6756","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6757","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6758","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"6759","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6760","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"6761","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6762","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6763","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"6764","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"6765","EUCAST 2020","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"6766","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"6767","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6768","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6769","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6770","EUCAST 2020","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test."
|
|
"6771","EUCAST 2020","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"6772","EUCAST 2020","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"6773","EUCAST 2020","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6774","EUCAST 2020","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6775","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"6776","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA
|
|
"6777","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6778","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,24,FALSE,FALSE,NA
|
|
"6779","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6780","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"6781","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6782","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6783","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"6784","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
|
|
ND = No ECOFF available."
|
|
"6785","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",14,14,FALSE,FALSE,NA
|
|
"6786","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6787","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6788","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6789","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6790","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA
|
|
"6791","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6792","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6793","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"6794","EUCAST 2020","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"6795","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6796","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6797","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6798","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"6799","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"6800","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6801","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6802","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6803","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6804","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6805","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6806","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6807","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,FALSE,FALSE,NA
|
|
"6808","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",19,19,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6809","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6810","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6811","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"6812","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6813","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6814","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6815","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6816","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6817","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6818","EUCAST 2020","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"6819","EUCAST 2020","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6820","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6821","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6822","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6823","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6824","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,15,FALSE,FALSE,NA
|
|
"6825","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"6826","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6827","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6828","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6829","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6830","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6831","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6832","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6833","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6834","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6835","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6836","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,17,FALSE,FALSE,NA
|
|
"6837","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6838","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6839","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6840","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6841","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6842","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6843","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"6844","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6845","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,NA
|
|
"6846","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6847","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"6848","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA
|
|
"6849","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA
|
|
"6850","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
|
"6851","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6852","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6853","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6854","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6855","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6856","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"6857","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,0.5,FALSE,FALSE,NA
|
|
"6858","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"6859","EUCAST 2020","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"6860","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6861","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6862","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6863","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6864","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6865","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6866","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6867","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6868","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6869","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6870","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"6871","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6872","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6873","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6874","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6875","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6876","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6877","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6878","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,22,FALSE,FALSE,NA
|
|
"6879","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6880","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6881","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA
|
|
"6882","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6883","EUCAST 2020","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6884","EUCAST 2020","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6885","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"6886","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6887","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6888","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6889","EUCAST 2020","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"6890","EUCAST 2020","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"6891","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA
|
|
"6892","EUCAST 2020","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below."
|
|
"6893","EUCAST 2020","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"6894","EUCAST 2020","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
|
|
"6895","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,17,FALSE,FALSE,NA
|
|
"6896","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.5,FALSE,FALSE,NA
|
|
"6897","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"6898","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6899","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"6900","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6901","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"6902","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6903","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6904","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"6905","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6906","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6907","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6908","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"6909","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6910","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"6911","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6912","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"6913","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"6914","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6915","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"6916","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6917","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"6918","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6919","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CZO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6920","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",17,17,FALSE,FALSE,NA
|
|
"6921","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6922","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6923","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"6924","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6925","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6926","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6927","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6928","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,12,FALSE,FALSE,NA
|
|
"6929","EUCAST 2020","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"6930","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,2,FALSE,FALSE,NA
|
|
"6931","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6932","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6933","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6934","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"6935","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6936","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"6937","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6938","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"6939","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6940","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"6941","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6942","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6943","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6944","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6945","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"6946","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"6947","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"6948","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"6949","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"6950","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"6951","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6952","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"6953","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,TRUE,FALSE,NA
|
|
"6954","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"6955","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6956","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"6957","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"6958","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"6959","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA
|
|
"6960","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"6961","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"6962","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"6963","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"6964","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6965","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"6966","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,TRUE,FALSE,NA
|
|
"6967","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"6968","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6969","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"6970","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6971","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,NA
|
|
"6972","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA
|
|
"6973","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"6974","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA
|
|
"6975","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"6976","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"6977","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30/10 mcg",22,22,FALSE,FALSE,"[4] See table of dosages for dosing for different indications."
|
|
"6978","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications."
|
|
"6979","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"6980","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"6981","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"6982","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA
|
|
"6983","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",24,24,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"6984","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",24,24,TRUE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"6985","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"6986","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"6987","EUCAST 2020","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"6988","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6989","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6990","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"6991","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"6992","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6993","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"6994","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
|
|
"6995","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,17,FALSE,FALSE,NA
|
|
"6996","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA
|
|
"6997","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"6998","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA
|
|
"6999","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"7000","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7001","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7002","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"7003","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7004","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"7005","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"7006","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7007","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"7008","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7009","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,22,TRUE,FALSE,NA
|
|
"7010","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,TRUE,FALSE,NA
|
|
"7011","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"7012","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7013","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7014","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
|
|
"7015","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",20,17,FALSE,FALSE,NA
|
|
"7016","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7017","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"7018","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
|
|
"7019","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7020","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7021","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"7022","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7023","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","75 mcg",23,20,FALSE,FALSE,NA
|
|
"7024","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7025","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,NA
|
|
"7026","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA
|
|
"7027","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"7028","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"7029","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"7030","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/."
|
|
"7031","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7032","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7033","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",20,17,FALSE,FALSE,NA
|
|
"7034","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7035","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,17,FALSE,FALSE,NA
|
|
"7036","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7037","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",50,21,FALSE,FALSE,NA
|
|
"7038","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,1,FALSE,FALSE,NA
|
|
"7039","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"7040","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"7041","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7042","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"7043","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7044","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,20,FALSE,FALSE,NA
|
|
"7045","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7046","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,15,FALSE,FALSE,NA
|
|
"7047","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7048","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"NET","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"7049","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"NET","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7050","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7051","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7052","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"7053","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7054","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"7055","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7056","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"7057","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA
|
|
"7058","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"7059","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"7060","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7061","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"7062","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA
|
|
"7063","EUCAST 2019","human","human","DISK","screen","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"7064","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"7065","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7066","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"7067","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7068","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"7069","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7070","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",26,26,FALSE,FALSE,NA
|
|
"7071","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7072","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note"
|
|
"7073","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA
|
|
"7074","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
|
|
"7075","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",31,31,FALSE,FALSE,NA
|
|
"7076","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7077","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",16,16,TRUE,FALSE,NA
|
|
"7078","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA
|
|
"7079","EUCAST 2019","human","human","DISK","screen","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
|
|
"7080","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",21,21,FALSE,FALSE,NA
|
|
"7081","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7082","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"7083","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7084","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method."
|
|
"7085","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7086","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",29,26,FALSE,FALSE,NA
|
|
"7087","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7088","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,21,FALSE,FALSE,NA
|
|
"7089","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7090","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"7091","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7092","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"7093","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7094","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,24,FALSE,FALSE,NA
|
|
"7095","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7096","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7097","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7098","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"7099","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7100","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"7101","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"7102","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"7103","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"7104","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"7105","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7106","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"7107","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
|
|
"7108","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"7109","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline."
|
|
"7110","EUCAST 2019","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"7111","EUCAST 2019","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
|
|
"7112","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"7113","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7114","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",20,20,FALSE,FALSE,NA
|
|
"7115","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7116","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"GEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",23,23,FALSE,FALSE,NA
|
|
"7117","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"GEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7118","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"7119","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7120","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA
|
|
"7121","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7122","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","1 unit",29,29,FALSE,FALSE,NA
|
|
"7123","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7124","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,25,FALSE,FALSE,NA
|
|
"7125","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"7126","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,24,FALSE,FALSE,NA
|
|
"7127","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7128","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
|
|
"7129","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7130","EUCAST 2019","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method."
|
|
"7131","EUCAST 2019","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"7132","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
|
|
"7133","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",10,8,FALSE,FALSE,NA
|
|
"7134","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA
|
|
"7135","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
|
|
"7136","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7137","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,TRUE,FALSE,NA
|
|
"7138","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7139","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,18,FALSE,FALSE,NA
|
|
"7140","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA
|
|
"7141","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",19,19,FALSE,FALSE,NA
|
|
"7142","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7143","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7144","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,TRUE,FALSE,NA
|
|
"7145","EUCAST 2019","human","human","DISK","screen","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,12,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
|
|
"7146","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
|
|
"7147","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",16,16,FALSE,FALSE,NA
|
|
"7148","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7149","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7150","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7151","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation."
|
|
"7152","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7153","EUCAST 2019","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",22,20,FALSE,FALSE,NA
|
|
"7154","EUCAST 2019","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7155","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"7156","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA
|
|
"7157","EUCAST 2019","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"7158","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"7159","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7160","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA
|
|
"7161","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7162","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli."
|
|
"7163","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"7164","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",11,11,TRUE,FALSE,NA
|
|
"7165","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA
|
|
"7166","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",15,15,TRUE,FALSE,NA
|
|
"7167","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA
|
|
"7168","EUCAST 2019","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method."
|
|
"7169","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
|
|
"7170","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7171","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7172","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7173","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7174","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7175","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7176","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7177","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7178","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7179","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7180","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7181","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"7182","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7183","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7184","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7185","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7186","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7187","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7188","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7189","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7190","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7191","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7192","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7193","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7194","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7195","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7196","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"7197","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7198","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
|
|
"7199","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7200","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7201","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7202","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7203","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7204","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7205","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7206","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility."
|
|
"7207","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7208","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7209","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",16,16,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"7210","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"7211","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
|
|
"7212","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7213","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7214","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"7215","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7216","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7217","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7218","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)."
|
|
"7219","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7220","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"7221","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7222","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7223","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7224","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7225","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7226","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7227","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7228","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,27,FALSE,FALSE,NA
|
|
"7229","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7230","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"7231","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7232","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7233","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7234","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)."
|
|
"7235","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7236","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7237","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7238","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7239","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7240","EUCAST 2019","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7241","EUCAST 2019","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7242","EUCAST 2019","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Meropenem is the only carbapenem used for meningitis."
|
|
"7243","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7244","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7245","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7246","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7247","EUCAST 2019","human","human","DISK","screen","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"7248","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7249","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7250","EUCAST 2019","human","human","DISK","screen","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7251","EUCAST 2019","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",18,18,FALSE,FALSE,NA
|
|
"7252","EUCAST 2019","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7253","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"7254","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7255","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7256","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7257","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7258","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
|
|
"7259","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7260","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"7261","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
|
|
"7262","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"7263","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"7264","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7265","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility."
|
|
"7266","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,NA
|
|
"7267","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7268","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,NA
|
|
"7269","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7270","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",29,29,FALSE,FALSE,NA
|
|
"7271","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7272","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7273","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,20,FALSE,FALSE,NA
|
|
"7274","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7275","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,NA
|
|
"7276","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7277","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",30,30,FALSE,FALSE,NA
|
|
"7278","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"7279","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",25,25,FALSE,FALSE,NA
|
|
"7280","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"7281","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,20,FALSE,FALSE,NA
|
|
"7282","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7283","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7284","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7285","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,NA
|
|
"7286","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7287","EUCAST 2019","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"7288","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"7289","EUCAST 2019","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7290","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA
|
|
"7291","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli."
|
|
"7292","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"7293","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",16,16,FALSE,FALSE,NA
|
|
"7294","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7295","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",25,25,FALSE,FALSE,NA
|
|
"7296","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7297","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",26,26,FALSE,FALSE,NA
|
|
"7298","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7299","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","1 unit",13,13,FALSE,FALSE,NA
|
|
"7300","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7301","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7302","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7303","EUCAST 2019","human","human","DISK",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7304","EUCAST 2019","human","human","MIC",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7305","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",19,19,FALSE,FALSE,NA
|
|
"7306","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7307","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7308","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,18,FALSE,FALSE,NA
|
|
"7309","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7310","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Breakpoints relate to topical use only."
|
|
"7311","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Breakpoints relate to topical use only."
|
|
"7312","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7313","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7314","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7315","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,NA
|
|
"7316","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7317","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"7318","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7319","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,18,FALSE,FALSE,NA
|
|
"7320","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,21,FALSE,FALSE,NA
|
|
"7321","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA
|
|
"7322","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,NA
|
|
"7323","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7324","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7325","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7326","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7327","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7328","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",20,20,FALSE,FALSE,NA
|
|
"7329","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7330","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7331","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7332","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7333","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7334","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7335","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7336","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7337","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7338","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7339","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7340","EUCAST 2019","human","human","DISK","screen","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"7341","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7342","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7343","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7344","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
|
|
"7345","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7346","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7347","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7348","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7349","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"7350","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7351","EUCAST 2019","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established."
|
|
"7352","EUCAST 2019","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7353","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7354","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.06,FALSE,FALSE,NA
|
|
"7355","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7356","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7357","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.25,FALSE,FALSE,NA
|
|
"7358","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
|
|
"7359","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,FALSE,FALSE,NA
|
|
"7360","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7361","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"7362","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA
|
|
"7363","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7364","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
|
|
"7365","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7366","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7367","EUCAST 2019","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7368","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"7369","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.25,FALSE,FALSE,NA
|
|
"7370","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] For prophylaxis of meningitis only (refer to national guidelines)."
|
|
"7371","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
|
|
"7372","EUCAST 2019","human","human","DISK",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7373","EUCAST 2019","human","human","MIC",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7374","EUCAST 2019","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"7375","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA
|
|
"7376","EUCAST 2019","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7377","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA
|
|
"7378","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli."
|
|
"7379","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination."
|
|
"7380","EUCAST 2019","human","human","DISK",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7381","EUCAST 2019","human","human","MIC",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
|
"7382","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,15,FALSE,FALSE,NA
|
|
"7383","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7384","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"7385","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA
|
|
"7386","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA
|
|
"7387","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7388","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"7389","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7390","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"7391","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"7392","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7393","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"GEN","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,FALSE,FALSE,NA
|
|
"7394","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"GEN","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7395","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,NA
|
|
"7396","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7397","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"7398","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7399","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,18,FALSE,FALSE,NA
|
|
"7400","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7401","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"NET","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,12,FALSE,FALSE,NA
|
|
"7402","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"NET","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7403","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,18,FALSE,FALSE,NA
|
|
"7404","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA
|
|
"7405","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","75/10 mcg",18,18,FALSE,FALSE,NA
|
|
"7406","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7407","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","75 mcg",18,18,FALSE,FALSE,NA
|
|
"7408","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA
|
|
"7409","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",16,16,FALSE,FALSE,NA
|
|
"7410","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA
|
|
"7411","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",18,18,FALSE,FALSE,NA
|
|
"7412","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7413","EUCAST 2019","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10/4 mcg",17,17,FALSE,FALSE,NA
|
|
"7414","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"7415","EUCAST 2019","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30/10 mcg",24,24,FALSE,FALSE,NA
|
|
"7416","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7417","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"7418","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",15,15,FALSE,FALSE,NA
|
|
"7419","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7420","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7421","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7422","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"7423","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7424","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA
|
|
"7425","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA
|
|
"7426","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA
|
|
"7427","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
|
|
"7428","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA
|
|
"7429","EUCAST 2019","human","human","DISK","screen","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
|
|
"7430","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","1 unit",17,17,FALSE,FALSE,NA
|
|
"7431","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7432","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7433","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7434","EUCAST 2019","human","human","DISK","screen","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test."
|
|
"7435","EUCAST 2019","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"7436","EUCAST 2019","human","human","DISK","screen","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",24,24,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
|
|
"7437","EUCAST 2019","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7438","EUCAST 2019","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7439","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7440","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA
|
|
"7441","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7442","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"7443","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
|
|
"7444","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7445","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7446","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7447","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7448","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7449","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7450","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",19,16,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7451","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7452","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7453","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7454","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",19,19,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7455","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7456","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7457","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7458","EUCAST 2019","human","human","DISK","screen","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"7459","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7460","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7461","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7462","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,15,FALSE,FALSE,NA
|
|
"7463","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"7464","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7465","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7466","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7467","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7468","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7469","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7470","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7471","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7472","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7473","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,17,FALSE,FALSE,NA
|
|
"7474","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7475","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7476","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7477","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7478","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7479","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7480","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7481","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",15,15,TRUE,FALSE,NA
|
|
"7482","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA
|
|
"7483","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA
|
|
"7484","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7485","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
|
|
"7486","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
|
|
"7487","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
|
|
"7488","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7489","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7490","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,28,FALSE,FALSE,NA
|
|
"7491","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.5,FALSE,FALSE,NA
|
|
"7492","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,21,FALSE,FALSE,NA
|
|
"7493","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7494","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"7495","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"7496","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7497","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7498","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7499","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"7500","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"7501","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7502","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7503","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7504","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7505","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7506","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7507","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7508","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7509","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"7510","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7511","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7512","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7513","EUCAST 2019","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
|
|
"7514","EUCAST 2019","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Meropenem is the only carbapenem used for meningitis."
|
|
"7515","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note"
|
|
"7516","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7517","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7518","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7519","EUCAST 2019","human","human","DISK","screen","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"7520","EUCAST 2019","human","human","DISK","screen","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below."
|
|
"7521","EUCAST 2019","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
|
|
"7522","EUCAST 2019","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
|
|
"7523","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,17,FALSE,FALSE,NA
|
|
"7524","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA
|
|
"7525","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
|
|
"7526","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7527","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7528","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7529","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
|
|
"7530","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7531","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7532","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,NA
|
|
"7533","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7534","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7535","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7536","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",21,15,FALSE,FALSE,NA
|
|
"7537","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"7538","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA
|
|
"7539","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"7540","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
|
|
"7541","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"7542","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7543","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"7544","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7545","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"7546","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7547","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CZO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7548","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA
|
|
"7549","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7550","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
|
|
"7551","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7552","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7553","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA
|
|
"7554","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,12,FALSE,FALSE,NA
|
|
"7555","EUCAST 2019","human","human","DISK","screen","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
|
|
"7556","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,2,FALSE,FALSE,NA
|
|
"7557","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7558","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7559","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7560","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
|
"7561","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"7562","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"7563","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7564","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,TRUE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7565","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,15,FALSE,FALSE,NA
|
|
"7566","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7567","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",14,14,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"7568","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm."
|
|
"7569","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm."
|
|
"7570","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"7571","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
|
|
"7572","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"7573","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7574","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,FALSE,FALSE,NA
|
|
"7575","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7576","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,TRUE,FALSE,NA
|
|
"7577","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA
|
|
"7578","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",12,12,TRUE,FALSE,NA
|
|
"7579","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA
|
|
"7580","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",17,17,FALSE,FALSE,NA
|
|
"7581","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA
|
|
"7582","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,22,FALSE,FALSE,NA
|
|
"7583","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7584","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
|
|
"7585","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,21,TRUE,FALSE,NA
|
|
"7586","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA
|
|
"7587","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,NA
|
|
"7588","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7589","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,NA
|
|
"7590","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7591","EUCAST 2019","human","human","DISK","UTI only","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,23,TRUE,FALSE,NA
|
|
"7592","EUCAST 2019","human","human","MIC","UTI only","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA
|
|
"7593","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,17,FALSE,FALSE,NA
|
|
"7594","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA
|
|
"7595","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10/4 mcg",13,13,FALSE,FALSE,NA
|
|
"7596","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
|
|
"7597","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30/10 mcg",23,23,FALSE,FALSE,NA
|
|
"7598","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
|
"7599","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",25,25,FALSE,FALSE,NA
|
|
"7600","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA
|
|
"7601","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,24,FALSE,FALSE,NA
|
|
"7602","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA
|
|
"7603","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","200 mcg",24,24,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"7604","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","200 mcg",24,24,TRUE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
|
|
"7605","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"7606","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
|
|
"7607","EUCAST 2019","human","human","DISK","screen","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
|
|
"7608","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,14,FALSE,FALSE,NA
|
|
"7609","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7610","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,17,FALSE,FALSE,NA
|
|
"7611","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7612","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",14,14,TRUE,FALSE,NA
|
|
"7613","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA
|
|
"7614","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,19,FALSE,FALSE,NA
|
|
"7615","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA
|
|
"7616","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,16,FALSE,FALSE,NA
|
|
"7617","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA
|
|
"7618","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
|
|
"7619","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,NA
|
|
"7620","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA
|
|
"7621","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"NET","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,12,FALSE,FALSE,NA
|
|
"7622","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"NET","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7623","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,TRUE,FALSE,NA
|
|
"7624","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,TRUE,FALSE,NA
|
|
"7625","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",24,22,FALSE,FALSE,NA
|
|
"7626","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA
|
|
"7627","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",20,17,FALSE,FALSE,NA
|
|
"7628","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7629","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
|
|
"7630","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins.
|
|
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
|
"7631","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7632","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
|
"7633","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","75/10 mcg",23,20,FALSE,FALSE,NA
|
|
"7634","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
|
"7635","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","75 mcg",23,20,FALSE,FALSE,NA
|
|
"7636","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA
|
|
"7637","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",18,15,TRUE,FALSE,NA
|
|
"7638","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,TRUE,FALSE,NA
|
|
"7639","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,14,FALSE,FALSE,NA
|
|
"7640","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA
|
|
"7641","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",20,17,FALSE,FALSE,NA
|
|
"7642","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|